<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doxorubicin (conventional): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doxorubicin (conventional): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Doxorubicin (conventional): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12401" href="/d/html/12401.html" rel="external">see "Doxorubicin (conventional): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13254" href="/d/html/13254.html" rel="external">see "Doxorubicin (conventional): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708686"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiomyopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Myocardial damage, including acute left ventricular failure, can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m<sup>2</sup> to 500 mg/m<sup>2</sup> when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction before and regularly during and after treatment with doxorubicin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extravasation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. Immediately terminate the drug and apply ice to the affected area.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Secondary malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Secondary acute myelogenous leukemia and myelodysplastic syndrome occur at a higher incidence in patients treated with anthracyclines, including doxorubicin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myelosuppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F163149"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adriamycin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F163199"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anthracycline;</li>
<li>
                        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F163154"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Monitor cumulative dose (doxorubicin and other anthracyclines) received; the risk for cardiomyopathy increases as the cumulative dose increases and is also dependent on other/additional risk factors. Actively manage modifiable cardiac risk factors (smoking, hypertension, diabetes, dyslipidemia, obesity) before initiating treatment (ASCO [Armenian 2017]). Doxorubicin is associated with a moderate to high emetic potential (depending on dose or regimen); antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]). Do <b>NOT</b> substitute conventional doxorubicin for or with doxorubicin (liposomal); products are different and are <b>NOT</b> interchangeable. Use caution when selecting product for preparation and dispensing (both products are the same concentration).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b5fd58c-2ade-43ce-a3f5-be85a60e433f">Acute lymphoblastic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (off-label dosing): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyper-CVAD regimen:</i>
<b>IV:</b> 50 mg/m<sup>2</sup> on day 4 of Courses 1, 3, 5, and 7 (in combination with cyclophosphamide, vincristine, and dexamethasone); alternating cycles with high-dose methotrexate and cytarabine (Kantarjian 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CALGB 8811 regimen:</i>
<b>IV:</b> 30 mg/m<sup>2</sup> on days 1, 8 and 15 of late intensification (Course 4; 8-week cycle); in combination with vincristine, dexamethasone, cyclophosphamide, thioguanine, and cytarabine (Larson 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DFCI Consortium regimen:</i> Patients ≤50 years of age:<b> IV: </b>Induction phase: 30 mg/m<sup>2</sup> on days 1 and 2 (4-week treatment cycle); CNS therapy phase: 30 mg/m<sup>2</sup> for one dose (3-week treatment cycle); Intensification phase: 30 mg/m<sup>2</sup> on day 1 (3-week cycle; continue to a cumulative doxorubicin dose of 300 mg/m<sup>2</sup>); Continuation phase: 30 mg/m<sup>2</sup> on day 1 (3-week cycle; continue to a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> [if not already reached]); phases are part of combination chemotherapy; refer to protocol for details (DeAngelo 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bdf93c9f-b469-4ebb-a761-64ccd7863dae">Adrenocortical carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenocortical carcinoma, advanced (off-label use): IV:</b> 40 mg/m<sup>2</sup> on day 1 every 4 weeks (in combination with cisplatin, etoposide, and mitotane) (Fassnacht 2012) <b>or</b> 20 mg/m<sup>2</sup> on days 1 and 8 every 4 weeks (in combination with cisplatin, etoposide, and mitotane) until disease progression or unacceptable toxicity up to a maximum of 6 cycles (Berruti 2005).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a881e1b5-4635-4167-8c83-7c4811057163">Adult T-cell leukemia/lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adult T-cell leukemia/lymphoma (off-label use): IV:</b> 40 mg/m<sup>2</sup> on day 1 and 30 mg/m<sup>2</sup> on day 8 every 28 days (as part of the VCAP-AMP-VECP multiagent chemotherapy regimen) for 6 cycles (Tsukasaki 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22fb6a91-1983-4ae6-9999-c914c397b3b8">Bladder cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer, advanced (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced or metastatic disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Dose-dense MVAC regimen: <b>IV:</b> 30 mg/m<sup>2</sup> on day 2 every 14 days (in combination with methotrexate, vinblastine, cisplatin, and growth factor support) until disease progression or unacceptable toxicity (Sternberg 2001; Sternberg 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">MVAC regimen: <b>IV:</b> 30 mg/m<sup>2</sup> on day 2 every 28 days (in combination with methotrexate, vinblastine, and cisplatin) for up to 6 cycles (von der Maase 2000) <b>or</b> 30 mg/m<sup>2</sup> on day 2 every 28 days (in combination with methotrexate, vinblastine, and cisplatin) until disease progression or unacceptable toxicity (Sternberg 2001; Sternberg 2006) <b>or</b> 30 mg/m<sup>2</sup> on day 1 every 28 days (in combination with methotrexate, vinblastine, cisplatin, and filgrastim) for up to 6 cycles or until loss of clinical benefit (Bamias 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neoadjuvant treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients with non-organ confined disease at cystectomy who did not receive cisplatin-based neoadjuvant chemotherapy should be offered an adjuvant cisplatin-based chemotherapy regimen (AUA/ASCO/ASTRO/SUO [Chang 2017]).</p>
<p style="text-indent:-2em;margin-left:8em;">Dose-dense MVAC regimen: <b>IV:</b> 30 mg/m<sup>2</sup> on day 1 or on day 2 every 14 days (in combination with methotrexate, vinblastine, cisplatin, and pegfilgrastim) for 3 or 4 cycles (Choueiri 2014; Plimack 2014).</p>
<p style="text-indent:-2em;margin-left:8em;">MVAC regimen: <b>IV:</b> 30 mg/m<sup>2</sup> on day 2 every 28 days (in combination with methotrexate, vinblastine, and cisplatin) for 3 cycles (Grossman 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Small cell carcinoma of the bladder: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Neoadjuvant treatment: <b>IV:</b> 25 mg/m<sup>2</sup> on days 1 to 3 every 21 days (in combination with ifosfamide, mesna, and growth factor support; IA cycle); IA cycle alternates with etoposide and cisplatin (EP cycle) for a total of 4 cycles (2 cycles of IA and 2 cycles of EP) (Siefker-Radtke 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">Metastatic disease: <b>IV:</b> 25 mg/m<sup>2</sup> on days 1 to 3 every 21 days (IA cycle); IA cycle alternates with EP cycle for 2 cycles beyond maximal response (Siefker-Radtke 2009).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f629398a-17b2-4a1a-8177-10deeef034f4">Breast cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AC regimen: </i>
<b>IV:</b> 60 mg/m<sup>2</sup> on day 1 every 21 days for 4 cycles (in combination with cyclophosphamide) (Fisher 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose dense AC (ddAC) followed by T regimen: </i>
<b>IV:</b> 60 mg/m<sup>2</sup> on day 1 every 14 days for 4 cycles (in combination with cyclophosphamide [and filgrastim], then followed by paclitaxel) (Citron 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AC-TH (HER-2 positive): </i>
<b>IV: </b>60 mg/m<sup>2</sup> once every 3 weeks (in combination with cyclophosphamide) for 4 cycles, followed by paclitaxel and trastuzumab (Romond 2005) <b>or</b> 60 mg/m<sup>2</sup> every 2 weeks (in combination with cyclophosphamide) for 4 cycles (with growth factor support; followed by paclitaxel and trastuzumab) (Dang 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AC-THP (neoadjuvant therapy; HER-2 positive): </i>
<b>IV: </b>60 mg/m<sup>2</sup> once every 2 weeks for 4 cycles (in combination with cyclophosphamide; followed by paclitaxel, pertuzumab, and trastuzumab) (Swain 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TAC regimen:</i>
<b>IV:</b> 50 mg/m<sup>2</sup> on day 1 every 21 days for 6 cycles (in combination with docetaxel and cyclophosphamide) (Martin 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Keynote-</i>
<i>522 regimen (early triple-negative breast cancer; neoadjuvant therapy): </i>
<b>IV: </b>60 mg/m<sup>2</sup> once every 3 weeks (in combination with cyclophosphamide [AC] and pembrolizumab) for 4 cycles (second neoadjuvant treatment); first neoadjuvant treatment was 4 cycles of pembrolizumab/paclitaxel/carboplatin, followed by second neoadjuvant treatment of 4 cycles of AC plus pembrolizumab. After definitive surgery, patients received adjuvant therapy with pembrolizumab and radiation for up to 9 cycles. Refer to protocol for further information (Schmid 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5a0b08f-0433-45b2-907f-e6540531abb0">Endometrial carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial carcinoma, advanced (off-label use):</b>
<b>IV:</b> 60 mg/m<sup>2</sup> on day 1 every 21 days for 8 cycles; maximum cumulative dose: 420 mg/m<sup>2</sup> (in combination with cisplatin) (Randall 2006) <b>or</b> 45 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with cisplatin and optional growth factor support) for up to 6 cycles (Homesley 2009) <b>or</b> 60 mg/m<sup>2</sup> (as a single agent) once every 3 weeks until disease progression or unacceptable toxicity (Cohen 1986; McMeekin 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma (off-label dosing): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VDC/IE regimen:</i> Adults ≤30 years: <b>IV: </b>75 mg/m<sup>2</sup> on day 1 every 21 days for 5 cycles (in combination with vincristine and cyclophosphamide; after 5 cycles, dactinomycin replaced doxorubicin), alternating cycles with ifosfamide and etoposide for a total of 17 cycles (Grier 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAIA regimen:</i> Adults &lt;35 years: <b>IV: </b>30 mg/m<sup>2</sup>/day on days 1 and 2 every 21 days (doxorubicin alternates with dactinomycin; in combination with vincristine and ifosfamide) for14 cycles (Paulussen 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VIDE regimen:</i>
<b>IV:</b> 20 mg/m<sup>2</sup>/day over 4 hours on days 1 to 3 every 21 days for 6 cycles (in combination with vincristine, ifosfamide, and etoposide) (Juergens 2006).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="054cb2ee-5071-452f-bdc8-bc7d4d858b46">Hepatocellular cancer, intermediate stage, chemoembolization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular cancer, intermediate stage, chemoembolization (off-label use): Note: </b>Refer to protocol and institutional policies for additional dosing/administration details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conventional transcatheter arterial chemoembolization (cTACE):</i>
<b>Intra-arterial: </b>50 to 75 mg/m<sup>2</sup> (maximum: 150 mg) as a single dose via intra-arterial injection every 2 months for a maximum of 3 doses; dose may require adjustment based on bilirubin level (Lammer 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Drug-eluting bead-transcatheter arterial chemoembolization (DEB-TACE):</i>
<b>Intra-arterial: </b>150 mg administered via loaded drug-eluting bead every 2 months for a maximum of 3 doses (Lammer 2010); drug-eluting beads loaded with doses ranging from 25 to 150 mg have been shown to be safe and effective.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62741bde-a218-4ed4-b000-beb13ef61c16">Hepatocellular cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular cancer, metastatic (off-label use): IV:</b> 60 mg/m<sup>2</sup> on day 1 every 28 days (in combination with cisplatin) for up to 6 cycles (Lee 2004) or 60 mg/m<sup>2</sup> on day 1 every 21 days (in combination with cisplatin and capecitabine) for up to 6 cycles (Park 2006).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma (off-label dosing): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ABVD regimen:</i>
<b>IV: </b>25 mg/m<sup>2</sup> on days 1 and 15 every 28 days (in combination with bleomycin, vinblastine, and dacarbazine) for 2 to 4 cycles (Bonadonna 2004; Engert 2010). The number of cycles required and follow-up treatment may be determined by PET scan after 2 cycles (Johnson 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>A-AVD regimen: </i>
<b>IV: </b>25 mg/m<sup>2</sup> on days 1 and 15 every 4 weeks (in combination with brentuximab vedotin, vinblastine, and dacarbazine) for up to 6 cycles (Connors 2018). Administer primary prophylaxis with G-CSF (filgrastim) beginning with cycle 1.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEACOPP and escalated BEACOPP regimens:</i>
<b>IV: </b>25 mg/m<sup>2</sup> (BEACOPP) or 35 mg/m<sup>2</sup> (escalated BEACOPP) on day 1 every 21 days (in combination with bleomycin, etoposide, cyclophosphamide, vincristine, procarbazine, and prednisone) for 8 cycles (Diehl 2003; Engert 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Stanford V regimen:</i>
<b>IV: </b>25 mg/m<sup>2</sup> on weeks 1, 3, 5, 7, 9, and 11 of a 12-week cycle (in combination with mechlorethamine, vinblastine, vincristine, bleomycin, etoposide, and prednisone) (Horning 2002).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>PAD regimen: Induction:</i>
<b>IV: </b>9 mg/m<sup>2</sup>/day on days 1 to 4 for 3 cycles (in combination with bortezomib and dexamethasone) (Sonneveld 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VDT-PACE regimen:</i>
<b>IV: </b>10 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1 to 4 of each cycle (in combination with bortezomib, dexamethasone, thalidomide, cisplatin, cyclophosphamide, and etoposide) (Lee 2003; Pineda-Roman 2008).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2b9f607-2d7f-4f44-bd06-8eb8b9fdb18b">Neuroendocrine tumors, pancreatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumors, pancreatic (off-label use): IV:</b> 40 mg/m<sup>2</sup> on day 1 of a 28-day cycle (in combination with streptozocin and fluorouracil) until disease progression or unacceptable toxicity (Kouvaraki 2004) <b>or</b> 50 mg/m<sup>2</sup> on days 1 and 22 of a 6-week cycle (in combination with streptozocin) until disease progression or unacceptable toxicity (Moertel 1992).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas (off-label dosing): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Burkitt lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CALGB 10002 regimen</i>
<i> (cycles 3, 5, and 7): </i>
<b>IV:</b> 25 mg/m<sup>2</sup>/day on days 4 and 5 every 3 weeks (in combination with cyclophosphamide, vincristine, prednisone, ifosfamide, dexamethasone, methotrexate, leucovorin, cytarabine, etoposide, rituximab, intrathecal therapy, and filgrastim); refer to protocol for further information (Rizzieri 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyper-CVAD + rituximab regimen:</i>
<b>IV: </b>50 mg/m<sup>2</sup> administered as a continuous infusion over 24 hours on day 4 of Courses 1, 3, 5, and 7 (21-day treatment cycles; in combination with cyclophosphamide, vincristine, dexamethasone, and rituximab); alternating cycles with high-dose methotrexate and cytarabine (Thomas 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>R-CODOX-M/IVAC:</i> Cycles 1 and 3 (CODOX-M): <b>IV:</b> 50 mg/m<sup>2</sup> on day 1 (Barnes 2011; Lacasce 2004) <b>or</b> 40 mg/m<sup>2</sup> on day 1 (Mead 2002), in combination with cyclophosphamide, vincristine, methotrexate, and CNS prophylaxis; CODOX-M alternates with IVAC (ifosfamide, mesna, etoposide, cytarabine, and CNS prophylaxis) ± rituximab for a total of 4 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diffuse large B-cell lymphoma (DLBCL):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CHOP or RCHOP regimen:</i>
<b>IV: </b>50 mg/m<sup>2</sup> on day 1 every 21 days (in combination with cyclophosphamide, vincristine, and prednisone ± rituximab) (Coiffier 2010; McKelvey 1976).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dose-adjusted EPOCH or REPOCH regimen:</i>
<b>IV: </b>10 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1 to 4 every 21 days (in combination with etoposide, vincristine, cyclophosphamide, and prednisone ± rituximab) (Garcia-Suarez 2007; Wilson 2002).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pola-R-CHP regimen (previously untreated DLBCL): </i>
<b>IV:</b> 50 mg/m<sup>2</sup> on day 1 every 21 days (in combination with polatuzumab vedotin, rituximab, cyclophosphamide, and prednisone) for 6 cycles; following the completion of 6 cycles of Pola-R-CHP, rituximab monotherapy was continued for 2 cycles (Tilly 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Follicular lymphoma: </i>R-CHOP regimen: <b>IV: </b>50 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle for 6 to 8 cycles (in combination with rituximab, cyclophosphamide, vincristine, and prednisone) (Hiddemann 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mantle cell lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nordic regimen (Maxi-CHOP):</i>
<b>IV: </b>75 mg/m<sup>2</sup> on day 1 every 21 days (in combination with cyclophosphamide, vincristine, prednisone, and rituximab), alternating cycles with high-dose cytarabine (Geisler 2008).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>RCHOP/RDHAP:</i>
<b>IV: </b>50 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with rituximab, cyclophosphamide, vincristine, and prednisone), alternating or sequentially with RDHAP (rituximab, dexamethasone, cytarabine, and cisplatin) for a total of 6 cycles (3 cycles of each) followed by autologous stem cell transplant (Delarue 2013; Hermine 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peripheral T-cell lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>BV-CHP (or A-CHP) regimen:</i>
<b>IV: </b>50 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with brentuximab vedotin, cyclophosphamide, and prednisone) for 6 to 8 cycles (Horwitz 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CHOEP regimen:</i>
<b>IV: </b>50 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with cyclophosphamide, vincristine, etoposide, and prednisone) for 6 to 8 cycles (Pfreundschuh 2004; Schmitz 2010).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CHOP regimen: </i>
<b>IV: </b>50 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with cyclophosphamide, vincristine, and prednisone) for 6 to 8 cycles (Pfreundschuh 2004; Schmitz 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary mediastinal B-cell lymphoma:</i> DA-EPOCH-R regimen: <b>IV:</b> 10 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1 to 4 every 21 days, dose-adjusted for subsequent cycles based on neutrophil and platelet counts during nadir (in combination with etoposide, prednisone, vincristine, cyclophosphamide, rituximab, and filgrastim); repeat cycle every 3 weeks for a total of 6 to 8 cycles (Dunleavy 2013). Refer to protocol for dosage adjustments.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="892a32f8-154f-41d0-a59a-cc8169aa39d2">Osteosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteosarcoma (off-label dosing): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cisplatin/doxorubicin regimen:</i> Adults ≤40 years: <b>IV: </b>25 mg/m<sup>2</sup> (bolus infusion) on days 1 to 3 every 21 days (in combination with cisplatin) (Bramwell 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>High-dose methotrexate/cisplatin/doxorubicin/ifosfamide regimen: </i>Adults &lt;40 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Preoperative: <b>IV: </b>75 mg/m<sup>2</sup> administered as a continuous infusion over 24 hours on day 3 of weeks 1 and 7 (in combination with methotrexate, cisplatin, and ifosfamide) (Bacci 2003).</p>
<p style="text-indent:-2em;margin-left:6em;">Postoperative: <b>IV: </b>90 mg/m<sup>2</sup> administered as a continuous infusion over 24 hours on weeks 13, 22, and 31 (in combination with methotrexate, cisplatin, and ifosfamide) (Bacci 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>MAP regimen:</i> Adults ≤40 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Preoperative: <b>IV: </b>37.5 mg/m<sup>2</sup>/day administered as a continuous infusion (over 48 hours) days 1 and 2 of weeks 1 and 6 (in combination with cisplatin, high-dose methotrexate, and leucovorin rescue) (Bielack 2015; Marina 2016; Whelan 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">Postoperative: <b>IV: </b>37.5 mg/m<sup>2</sup>/day administered as a continuous infusion (over 48 hours) days 1 and 2 of weeks 12, 17, 22, and 26 (in combination with cisplatin, high-dose methotrexate, and leucovorin rescue); refer to protocol for criteria, frequency, and other specific information (Bielack 2015; Marina 2016; Whelan 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab7fd876-2a1c-4db1-a223-47d767048f2d">Renal carcinoma, advanced; with sarcomatoid features</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal carcinoma, advanced; with sarcomatoid features (off-label use):</b>
<b>IV:</b> 50 mg/m<sup>2</sup> on day 1 every 14 days (in combination with gemcitabine and growth factor support) for 6 to 9 cycles (Haas 2012).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="270634b2-fcd3-4cfe-a2cc-bdf414a12701">Salivary gland cancers, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Salivary gland cancers, advanced (off-label use): IV:</b> 50 mg/m<sup>2</sup> on day 1 every 21 days (in combination with cisplatin and cyclophosphamide); continue until disease progression or unacceptable toxicity (Lictra 1996) <b>or</b> 50 mg/m<sup>2</sup> on day 1 every 21 days (in combination with cisplatin and cyclophosphamide) for 6 to 8 cycles or until disease progression or unacceptable toxicity (Debaere 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a8afedf-539c-4478-9117-60bd80ef6fb6">Small cell lung cancer, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, recurrent (off-label dosing):</b>
<b>IV:</b>
<i>CAV regimen:</i> 45 mg/m<sup>2</sup> (maximum dose: 100 mg) on day 1 every 21 days (in combination with cyclophosphamide and vincristine) until disease progression or unacceptable toxicity or for at least 4 or 6 cycles past maximum response (von Pawel 1999).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="982f4303-339c-4c1a-99c3-5e173bacf459">Soft tissue sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonspecific histologies:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AD regimen:</i>
<b>IV: </b>60 mg/m<sup>2 </sup>on day 1 every 21 days (either as a bolus infusion or administered continuously over 96 hours; in combination with dacarbazine) (Zalupski 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AIM regimen (off-label dosing):</i>
<b>IV: </b>30 mg/m<sup>2</sup> on days 1 and 2 every 21 days (in combination with ifosfamide and mesna) (Edmonson 1993).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>MAID regimen (off-label dosing):</i>
<b>IV: </b>20 mg/m<sup>2</sup>/day as a continuous infusion on days 1 to 3 every 21 days (in combination with ifosfamide, mesna, and dacarbazine) (Elias 1989).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Single-agent regimen:</i>
<b>IV: </b>75 mg/m<sup>2</sup> on day 1 every 21 days until disease progression or unacceptable toxicity (Santoro 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rhabdomyosarcoma (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VAC/IE regimen:</i> Adults &lt;21 years: <b>IV: </b>37.5 mg/m<sup>2</sup> on days 1 and 2 (administered over 18 hours each day) every 6 weeks (in combination with vincristine and cyclophosphamide), alternating cycles with ifosfamide and etoposide (Arndt 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VAI regimen (based on a limited number of patients):</i> Adults: <b>IV: </b>25 mg/m<sup>2</sup>/day on days 1 to 3 every 21 days (in combination with vincristine and ifosfamide) (Ogilvie 2010).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e648efbf-f934-43db-a4e5-c06dfa2508f1">Thymomas and thymic malignancies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymomas and thymic malignancies (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CAP regimen:</i>
<b>IV: </b>50 mg/m<sup>2</sup> on day 1 every 21 days for up to 8 cycles (in combination with cisplatin and cyclophosphamide) (Loehrer 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CAP with prednisone regimen:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction: </i>
<b>IV: </b>20 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1 to 3 (total dose per cycle: 60 mg/m<sup>2</sup>) every 3 to 4 weeks (in combination with cyclophosphamide, cisplatin, and prednisone) for 3 cycles, followed by surgical resection, radiation, and consolidation chemotherapy (Kim 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation: <b>IV: </b>16 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1 to 3 (total dose per cycle: 48 mg/m<sup>2</sup>) every 3 to 4 weeks (in combination with cyclophosphamide, cisplatin, and prednisone) for 3 cycles. <b>Note: </b>During consolidation, cyclophosphamide, cisplatin, and doxorubicin were dosed at 80% of the induction therapy doses; refer to protocol for further information (Kim 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ADOC regimen:</i>
<b>IV: </b>40 mg/m<sup>2</sup> on day 1 every 21 days (in combination with cisplatin, vincristine, and cyclophosphamide) (Fornasiero 1991).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f9672781-bc35-4a58-905d-1d3589a2e99c">Uterine sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uterine sarcoma (off-label use): IV:</b> 60 mg/m<sup>2</sup> on day 1 every 21 days (either as a single agent or in combination with dacarbazine); maximum cumulative doxorubicin dose: 480 mg/m<sup>2</sup> (Omura 1983) <b>or</b> 50 mg/m<sup>2</sup> (over 15 minutes) on day 1 every 21 days; maximum cumulative dose: 450 mg/m<sup>2</sup> (in combination with ifosfamide/mesna) (Sutton 1996).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c80a4983-47b2-40ca-af06-20267a6401a8">Waldenstrom macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenstrom macroglobulinemia (off-label use): IV:</b>
<i>R-CHOP regimen:</i> 50 mg/m<sup>2</sup> on day 1 every 21 days for 4 to 8 cycles (in combination with cyclophosphamide, vincristine, prednisone, and rituximab) (Buske 2009).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991698"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sandhu.1','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sandhu.1','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (large V<sub>d</sub>): <b>IV:</b>
<b>Initial:</b> Consider administering 75% of the usual indication-specific dose. May increase to 100% of the usual indication-specific dose if well tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181','lexi-content-ref-8137454','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181','lexi-content-ref-8137454','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzable (large V<sub>d</sub>): <b>IV:</b>
<b>Initial:</b> Consider administering 75% of the usual indication-specific dose. May increase to 100% of the usual indication-specific dose if well tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: IV: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): IV: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989014"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The manufacturers' labeling recommends the following adjustments:</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 1.2 to 3 mg/dL: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 3.1 to 5 mg/dL: Administer 25% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment (Child-Pugh class C or bilirubin &gt;5 mg/dL): Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 1.2 to 2.9 mg/dL: Administer 50% of dose (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 3 to 5 mg/dL: Administer 25% of dose (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin &gt;5 mg/dL: Use is not recommended (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases 2 to 3 times ULN: Administer 75% of dose (Floyd 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases &gt;3 times ULN: Administer 50% of dose (Floyd 2006).</p></div>
<div class="block doo drugH1Div" id="F20341637"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p></div>
<div class="block dot drugH1Div" id="F5526740"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Cardiotoxicity: Discontinue in patients who develop signs/symptoms of cardiomyopathy. Consider dexrazoxane (if appropriate) to reduce cardiac toxicity in patients who have received a high cumulative dose of anthracycline therapy (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Asymptomatic cardiac dysfunction</i>
<i>:</i> Consider initiating heart failure medications (eg, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and/or beta blockers) in patients with asymptomatic (stage B) heart disease (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild cardiac dysfunction: </i>Continue treatment with close cardiovascular monitoring (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate or severe cardiac dysfunction: </i>Interrupt treatment and utilize a multidisciplinary approach when deciding if/when to restart. Initiation of heart failure medications is recommended (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptomatic cardiac dysfunction:</i> Initiate heart failure medications (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild cardiac dysfunction: </i>Consider a multidisciplinary approach for decisions regarding treatment interruption versus continuation (ESC [Lyon 2022]). <i></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate cardiac dysfunction: </i>Interrupt treatment; consider a multidisciplinary approach for decisions regarding treatment reinitiation (ESC [Lyon 2022]). <i></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe cardiac dysfunction: </i>Discontinue anthracycline therapy (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic toxicity: May require treatment delay or dose reduction (depending on the severity).</p>
<p style="text-indent:-2em;margin-left:2em;">Also refer to protocol and/or study reference for specific dosage adjustment details.</p></div>
<div class="block doe drugH1Div" id="F163155"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F163176"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13254" href="/d/html/13254.html" rel="external">see "Doxorubicin (conventional): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase; refer to individual protocols. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations.</p>
<p style="text-indent:0em;margin-top:2em;">Monitor cumulative anthracycline dose (combined); the risk for cardiomyopathy increases as the cumulative dose increases (&gt;250 mg/m<sup>2</sup> in pediatric patients &lt;18 years and 550 mg/m<sup>2</sup> in patients &gt;18 years); also dependent on other/additional risk factors; interpatient variability exists (eg, some patients may experience left ventricular dysfunction at lower doses) (ESC [Zamorano 2016]; Long-Term Follow-Up Guidelines [COG 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Doxorubicin is associated with a moderate or high emetic potential (depending on dose or regimen); antiemetics are recommended to prevent nausea and vomiting (POGO [Paw Cho Sing 2019]). Do <b>NOT </b>substitute conventional doxorubicin for or with doxorubicin (liposomal); products are different and are <b>NOT </b>interchangeable. Use caution when selecting product for preparation and dispensing (both products are the same concentration).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b5fd58c-2ade-43ce-a3f5-be85a60e433f">Acute lymphoblastic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute</b>
<b> lymphoblastic leukemia (ALL):</b> Limited data available: Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DFCI Consortium Protocol 00-01</i> (Vrooman 2013):</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: 30 mg/m<sup>2</sup>/day on days 0 and 1 of a 4-week cycle (in combination with dexrazoxane [high-risk patients], vincristine, methotrexate, <i>Escherichia coli</i> asparaginase, prednisone, intrathecal cytarabine, and intrathecal methotrexate/cytarabine/hydrocortisone).</p>
<p style="text-indent:-2em;margin-left:6em;">CNS therapy: High-risk patients: 30 mg/m<sup>2</sup>/day on day 1 of a 3-week cycle (in combination with dexrazoxane, vincristine, mercaptopurine, intrathecal methotrexate/cytarabine, and cranial radiation).</p>
<p style="text-indent:-2em;margin-left:6em;">Intensification: High-risk patients: 30 mg/m<sup>2</sup>/day on day 1 of every 3-week cycle (in combination with dexrazoxane, vincristine, mercaptopurine, <i>E. coli</i> asparaginase, prednisone or dexamethasone, and intrathecal methotrexate/cytarabine/hydrocortisone); cumulative doxorubicin dose: 300 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AALL0232 (High risk, newly diagnosed)</i> (Larsen 2016): Delayed Intensification I: 25 mg/m<sup>2</sup>/day on days 1, 8, and 15 of an 8-week cycle (in combination with vincristine, pegaspargase, dexamethasone, cytarabine, cyclophosphamide, thioguanine, and intrathecal methotrexate).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8696d93-f6f4-4866-8db5-8bddfaef0662">Desmoplastic small round cell tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Desmoplastic small round cell tumor (DSRCT):</b> Limited data available: Children and Adolescents: IV: <i>HD</i>
<i>-CAV regimen</i>: 25 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1, 2, and 3 (total course dose: 75 mg/m<sup>2</sup>) (in combination with vincristine and cyclophosphamide for courses 1, 2, 4, and 6) alternating cycles with ifosfamide and etoposide for courses 4, 5, and 7 (Kushner 1996).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing </b>
<b>sarcoma:</b> Limited data available: Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAC/IE regimen:</i> 75 mg/m<sup>2</sup>/day on day 1 every 21 days for 5 cycles (in combination with vincristine and cyclophosphamide; after 5 cycles, dactinomycin replaced doxorubicin), alternating cycles with ifosfamide and etoposide for a total of 17 cycles (Grier 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAIA regimen:</i> 30 mg/m<sup>2</sup>/day on days 1 and 2 every 21 days (doxorubicin alternates with dactinomycin; in combination with vincristine and ifosfamide) for 14 cycles (Paulussen 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VIDE regimen:</i> 20 mg/m<sup>2</sup>/day over 4 hours on days 1 to 3 every 21 days for 6 cycles (in combination with vincristine, ifosfamide, and etoposide) (Juergens 2006).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce17d3e0-5a62-4c43-92d4-7e6e951d1d27">Hepatoblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatoblastoma:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>INT-0098 protocol </i>(Ortega 2000): Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Regimen B (Stage I-Unfavorable Histology, II, III, IV): 20 mg/m<sup>2</sup>/day administered as a continuous infusion for 4 days (total dose per course: 80 mg/m<sup>2</sup>) (in combination with cisplatin).</p>
<p style="text-indent:-2em;margin-left:6em;">Regimen C (Stage I-Favorable Histology): 20 mg/m<sup>2</sup>/day on days 1, 2, and 3 every 3 weeks for 4 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>PLADO</i>
<i>regimen</i>: Children and Adolescents: IV: 30 mg/m<sup>2</sup>/day administered as a continuous infusion on days 2 and 3 (total dose per course: 60 mg/m<sup>2</sup>) every 21 days for up to 6 courses (in combination with cisplatin) administered preoperatively (Czauderna 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Siopel-3HR regimen:</i> High risk: Infants, Children, and Adolescents &lt;16 years: IV: 30 mg/m<sup>2</sup>/day administered as a continuous infusion over 48 hours (total dose per course: 60 mg/m<sup>2</sup> in combination with carboplatin and alternating with cisplatin) beginning on day 15 every 28 days (days 15, 43, and 71) for up to 3 preoperative cycles of doxorubicin/carboplatin. If the tumor is not resectable after 3 preoperative cycles another 2 cycles of doxorubicin/carboplatin may be given. Regardless of when surgery takes place a maximum of 5 cycles of each doxorubicin/carboplatin and cisplatin were administered (Zsíros 2010).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b> Limited data available: Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Low risk, lymphocyte-predominant Hodgkin lymphoma: <i>AV-PC regimen</i>: 50 mg/m<sup>2</sup>/day on day 1 of a 21-day cycle (in combination with vincristine, prednisone, cyclophosphamide) (Appel 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Low risk, classical Hodgkin lymphoma: <i>AVPC regimen</i>
<i>:</i> 25 mg/m<sup>2</sup>/day on days 1 and 2 of a 21-day cycle (in combination with vincristine, prednisone, cyclophosphamide) (Keller 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermediate or high risk<i>: ABVE-PC</i>
<i> regimen</i>: 30 mg/m<sup>2</sup>/day on days 0 and 1 of a 21-day cycle (in combination with bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide) (Schwartz 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Advanced stage or high risk:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AVBD regimen</i>: 25 mg/m<sup>2</sup>/day on days 0 and 14 of a 28-day cycle (in combination with bleomycin, vinblastine, and dacarbazine) (Kelly 2011).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>BEACOPP regimen</i>: 35 mg/m<sup>2</sup>/day administered on day 0 of a 21-day treatment cycle (in combination with bleomycin, etoposide, cyclophosphamide, vincristine, procarbazine, and prednisone) (Kelly 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f930c6e-27e7-4ef2-b112-96407f58305c">Neuroblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">High risk (Stage IV disease):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CAV-P/VP regimen</i>: Infants and Children: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">≤12 kg: 0.83 mg/<b>kg</b>/day as a continuous infusion on days 1, 2, and 3 (total dose: 2.49 mg/<b>kg</b>) of courses 1, 2, 4, and 6 (in combination with cyclophosphamide, and vincristine [CAV] with etoposide and cisplatin [P/VP] during courses 3, 5, and 7) (Park 2016).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;12 kg: 25 mg/m<sup>2</sup>/day as a continuous infusion on days 1, 2, and 3 (total dose: 75 mg/m<sup>2</sup>) of courses 1, 2, 4, and 6 (in combination with cyclophosphamide, and vincristine [CAV] with etoposide and cisplatin [P/VP] during courses 3, 5, and 7) (Kreissman 2013; Kushner 1994; Park 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cisplatin-Doxorubicin-Etoposide-Cyclophosphamide regimen</i>: Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;10 kg: 1 mg/<b>kg</b>/day on day 2 of a 28-day cycle (in combination with cisplatin, etoposide, and cyclophosphamide) for a total of 5 cycles (Parikh 2015).</p>
<p style="text-indent:-2em;margin-left:8em;">≥10 kg: 30 mg/m<sup>2</sup>/day on day 2 of a 28-day cycle (in combination with cisplatin, etoposide, and cyclophosphamide) for a total of 5 cycles (Matthay 1999; Parikh 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Unresectable disease: <i>CE-CAdO regimen</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 2 mg/<b>kg</b>/day on day 5 of cycles 3 and 4 (CAdO; 21-day cycles) (in combination with cyclophosphamide, vincristine [CAdO], and carboplatin and etoposide [CE]) (Rubie 2001).</p>
<p style="text-indent:-2em;margin-left:6em;">Children: IV: 60 mg/m<sup>2</sup>/day on day 5 of cycles 3 and 4 (CAdO; 21-day cycles) (in combination with cyclophosphamide, vincristine [CAdO], and carboplatin and etoposide [CE]) (Rubie 1998).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac1551d4-0bff-4d8a-8de4-b0eed5c04298">Non-Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma: </b>Limited data available: Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Anaplastic large cell lymphoma (ALCL):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>NHL-BFM 90 Regimen, Course B and BB</i>: 25 mg/m<sup>2</sup>/day infused over 1 hour on days 4 and 5 of a 21- to 28-day cycle (depending on neutrophil recovery) (in combination with dexamethasone, cyclophosphamide, methotrexate, and intrathecal prophylaxis therapy) (Seidemann 2001).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ALCL-99 Regimen, Course BM and BV</i>: 25 mg/m<sup>2</sup>/day on days 4 and 5 of a 21-day cycle (in combination with cyclophosphamide, methotrexate, vinblastine, and intrathecal prophylaxis therapy) (Wrobel 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Mature B-cell Lymphomas (Burkitt lymphoma, Burkitt-like lymphoma, etc):</p>
<p style="text-indent:-2em;margin-left:6em;">High risk (Group C):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>COPADM 1 and 2 regimen</i>: Induction: 60 mg/m<sup>2</sup>/day on day 2 of a 16- to 21-day cycle (depending on neutrophil recovery) (in combination with cyclophosphamide, vincristine, prednisone, methotrexate, and intrathecal chemotherapy [refer to protocol and institution guidelines]) (Cairo 2007; Goldman 2014).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>COPA regimen</i>: Maintenance 1 (M1) and 3 (M3): 60 mg/m<sup>2</sup>/day over 30 to 60 minutes on Day 2 (M1) or Day 1 (M3) (in combination with cyclophosphamide, vincristine, prednisone, with/without methotrexate) (Cairo 2007; Goldman 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">Intermediate risk (Group B): <i>COPADM 1 and 2</i>: Induction: 60 mg/m<sup>2</sup>/day over ≤1 hour on day 1 (in combination with cyclophosphamide, vincristine, prednisone, methotrexate with/without rituximab) (Goldman 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Primary mediastinal large B-cell lymphoma (PMBCL): Very limited data available: Children ≥9 years and Adolescents: <i>DA-EPOCH-R regimen</i>: IV: 10 mg/m<sup>2</sup>/day as a continuous infusion on days 1 to 4 (96 hours) (total dose: 40 mg/m<sup>2</sup> per course); dose-adjusted for subsequent cycles based on neutrophil and platelet counts during nadir (in combination with etoposide, vincristine, cyclophosphamide, prednisone, and rituximab) (Dunleavy 2013; Giulino-Roth 2017; Wilson 2013).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="892a32f8-154f-41d0-a59a-cc8169aa39d2">Osteosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteosarcoma: </b>Limited data available: Children and Adolescents: IV: <i>High-dose methotrexate/cisplatin/doxorubicin </i>
<i>(MAP)<i> regimen</i></i>:</p>
<p style="text-indent:-2em;margin-left:4em;">Preoperative: 37.5 mg/m<sup>2</sup>/day on days 1 and 2 of week 1 and 6 (in combination with cisplatin and alternating with cycles of methotrexate) (Marina 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Postoperative: 37.5 mg/m<sup>2</sup>/day on days 1 and 2 of weeks 12, 17, 22, and 26 (weeks 12 and 17 are in combination with cisplatin and alternating with methotrexate); refer to protocol for criteria, frequency, and other specific information (Marina 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5504217-4a06-41a9-8929-da042d28bae3">Rhabdomyosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma:</b> Limited data available: Children and Adolescents: IV: <i>VAC/IE regimen:</i> 37.5 mg/m<sup>2</sup>/day on days 1 and 2 (administered over 18 hours each day) every 6 weeks (in combination with vincristine and cyclophosphamide), alternating cycles with ifosfamide and etoposide (Arndt 1998).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8cead17-5b33-4326-9157-7fee0fdfa8f5">Wilms tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DD-4A regimen</i>: <b>Note:</b> Begin regimen when ANC ≥750 mm<sup>3</sup> and platelet count ≥75,000 mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: 1.5 mg/<b>kg</b>/day on day 1 of weeks 4 and 10 and then 1 mg/<b>kg</b>/day on day 1 of week 16 and 22 (in combination with dactinomycin and vincristine). Reduce dose by 50% (ie, 0.75 mg/<b>kg/</b>day) for the first dose given within 6 weeks following whole lung or whole abdominal radiation (but not after flank radiation) unless administered concurrently with the start of radiation therapy (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 45 mg/m<sup>2</sup>/day on day 1 of weeks 4 and 10 and then 30 mg/m<sup>2</sup>/day on day 1 of weeks 16 and 22 (in combination with dactinomycin and vincristine). Reduce dose by 50% (ie, 22.5 mg/m<sup>2</sup>/day) for the first dose given within 6 weeks following whole lung or whole abdominal radiation (but not after flank radiation) unless administered concurrently with the start of radiation therapy (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>NWTS-5 Regimen I (unresectable tumors or stage II to IV tumors with blastemal predominance at time of definitive surgical procedure at either week 6 or 12 or relapsed disease):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 1.5 mg/<b>kg</b>/day administered as an IV push on day 1 of weeks 7, 13, 19, and 25 (in combination with vincristine, cyclophosphamide, mesna, etoposide, and filgrastim); reduce dose by 50% (ie, 0.75 mg/<b>kg</b>) at week 6 if patient undergoes radiation; omit week 25 if patient received 6 or 12 weeks of preoperative therapy with Regimen VAD (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 45 mg/m<sup>2</sup>/day administered as IV push on day 1 of weeks 7, 13, 19, and 25 (in combination with vincristine, cyclophosphamide, mesna, etoposide, and filgrastim); reduce dose by 50% (ie, 22.5 mg/m<sup>2</sup>) at week 6 if patient undergoes radiation; omit week 25 if patient received 6 or 12 weeks of preoperative therapy with Regimen VAD (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Revised UH-1 Regimen: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 1.5 mg/<b>kg</b>/day administered as an IV push on day 1 of weeks 1, 10, 13, 22, and 28 (in combination with vincristine, cyclophosphamide, mesna, carboplatin, and filgrastim); reduce dose by 50% (0.75 mg/<b>kg</b>) if administered during or within 6 weeks of completing radiation; omit week 28 if patient received 6 weeks of Regimen VAD; omit weeks 13, 22, and 28 if patient received 12 weeks of Regimen VAD (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 45 mg/m<sup>2</sup>/day administered as IV push on day 1 of weeks 1, 10, 13, 22, and 28 (in combination with vincristine, cyclophosphamide, mesna, carboplatin, and filgrastim); reduce dose by 50% (22.5 mg/m<sup>2</sup>) if administered during or within 6 weeks of completing radiation; omit week 28 if patient received 6 weeks of Regimen VAD; omit weeks 13, 22, and 28 if patient received 12 weeks of Regimen VAD (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAD regimen:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 1.2 mg/<b>kg</b>/day on day 1 of weeks 1, 4, 7, and 10 (in combination with vincristine and dactinomycin) (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 35 mg/m<sup>2</sup>/day on day 1 of weeks 1, 4, 7, 10 (in combination with vincristine and dactinomycin) (Ehrlich 2017).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51094220"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">All patients: Mild, moderate, or severe impairment: There are no dosage adjustments provided in the manufacturers' labeling (has not been studied); however, adjustments are likely not necessary given limited renal excretion. The following adjustments have also been recommended (Aronoff 2007):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Supplemental dose is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51094221"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">The manufacturers' labeling recommends the following adjustments:</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin 1.2 to 3 mg/dL: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin 3.1 to 5 mg/dL: Administer 25% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe hepatic impairment (eg, bilirubin &gt;5 mg/dL): Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">The following adjustments have also been recommended based on experience in adults (Floyd 2006):</p>
<p style="text-indent:-2em;margin-left:6em;">Transaminases 2 to 3 times ULN: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Transaminases &gt;3 times ULN: Administer 50% of dose.</p></div>
<div class="block adr drugH1Div" id="F163119"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages may be reported as part of combination chemotherapy regimens in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy (1% to 20%; including cardiac insufficiency [&lt;1%], decreased left ventricular ejection fraction, heart failure, myocarditis, and pericarditis) (Felker 1999, Kumar 2012, Suto 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (92%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (34% to 37%; intractable vomiting: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression (can be severe; leukopenia [grades 3/4: ≤3%], neutropenia, and thrombocytopenia [grades 3/4: &lt;1%]), myelodysplastic syndrome (≤2%), secondary acute myelocytic leukemia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (2%; septic shock [2%])</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thrombosis (Jang 2019), atrial fibrillation (Hassan 2023), cardiogenic shock (Chong 2021), cardiotoxicity (including cardiomegaly, systolic heart murmur, and potential endomyocardial fibrosis) (Fitter 1981), phlebitis, phlebosclerosis, thromboembolism, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Nail hyperpigmentation (Bird 2006, Prajapati 2017), onycholysis (Jones 1989), palmar-plantar erythrodysesthesia (Jones 1989), pruritus, skin hyperpigmentation, skin photosensitivity, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, hot flash, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, dysgeusia (Rehwaldt 2009), esophagitis, gastrointestinal erosion, gastrointestinal hemorrhage, hematochezia, nausea, necrotizing enterocolitis, neutropenic typhlitis, oral mucosal hyperpigmentation, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Exacerbation of hepatitis B (including acute hepatic failure, increased serum alkaline phosphatase, increased serum bilirubin, and jaundice) (Hakami 2022), increased serum transaminases (including increased serum alanine aminotransferase, increased serum aspartate aminotransferase) (Hakami 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, chills, coma, malaise, peripheral motor neuropathy, peripheral sensory neuropathy, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, keratitis, lacrimation</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, radiation recall phenomenon (Burris 2010)</p></div>
<div class="block coi drugH1Div" id="F163133"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe hypersensitivity (including anaphylaxis) to doxorubicin or any component of the formulation; recent myocardial infarction (within past 4 to 6 weeks), severe myocardial insufficiency; severe persistent drug-induced myelosuppression; severe hepatic impairment (Child-Pugh class C or bilirubin &gt;5 mg/dL).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in the US labeling): Hypersensitivity to other anthracyclines or anthracenediones; severe arrhythmias; history of severe cardiac disease; previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones.</p></div>
<div class="block war drugH1Div" id="F163116"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe myelosuppression resulting in serious infection, septic shock, transfusion requirements, hospitalization, and death may occur. Dose-dependent and reversible neutropenia commonly occurs. Grade 3 and 4 leukopenia and thrombocytopenia have occurred; anemia may also occur. When administered on an every-3-week schedule, the nadir typically occurs 10 to 14 days after administration with cell count recovery by day 21.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiomyopathy: Myocardial damage (including acute left ventricular failure) can occur with doxorubicin with incidences from 1% to 20% for cumulative doses from 300 mg/m<sup>2</sup> to 500 mg/m<sup>2</sup> when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Delayed cardiotoxicity may occur late in treatment or within months to years after completion of therapy, and is typically manifested by decreased left ventricular ejection fraction (LVEF) and/or signs/symptoms of heart failure. The total cumulative doxorubicin dose should take into account prior treatment with other anthracyclines or anthracenediones. The risk for developing cardiotoxicity is estimated to range from 1% to 2% at cumulative lifetime doses of 300 mg/m<sup>2</sup> to 6% to 20% at cumulative lifetime doses of 500 mg/m<sup>2</sup>. The risk of cardiomyopathy is increased in patients who have received radiotherapy to the mediastinum or concomitant therapy with other known cardiotoxic agents such as cyclophosphamide and trastuzumab. Pericarditis and myocarditis have also been reported during or following doxorubicin treatment. Doxorubicin can result in arrhythmias, including life-threatening arrhythmias, during or within a few hours after administration and at any time point during treatment. Tachyarrhythmias (including sinus tachycardia, premature ventricular contractions, and ventricular tachycardia), and bradycardia may occur; ECG changes including non-specific ST-T wave changes, atrioventricular and bundle-branch block may also occur; ECG changes may be transient and self-limiting and may not require doxorubicin dose modifications.</p>
<p style="text-indent:-2em;margin-left:6em;">According to ASCO guidelines (ASCO [Armenian 2017]), the risk of cardiac dysfunction is increased with high-dose anthracycline therapy (eg, doxorubicin ≥250 mg/m<sup>2</sup>); high-dose radiotherapy (≥30 Gy) with the heart in the treatment field; lower-dose anthracyclines (eg, doxorubicin &lt;250 mg/m<sup>2</sup>) in combination with lower-dose radiotherapy (&lt;30 Gy) with the heart in the treatment field; lower-dose anthracyclines AND any of the following risk factors: ≥2 cardiovascular risk factors (including smoking, hypertension, diabetes, dyslipidemia, and obesity) during or after completion of therapy or age ≥60 years at cancer treatment, or compromised cardiac function (eg, borderline low LVEF [50% to 55%], history of MI, moderate or higher valvular heart disease) before or during treatment; treatment with lower-dose anthracycline followed by trastuzumab (sequential therapy); other risk factors for anthracycline-induced cardiotoxicity include age ≥60 years at time of treatment and 2 or more cardiovascular risk factors (smoking, hypertension, diabetes, dyslipidemia, or obesity) during or after treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; extravasation may result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. If extravasation is suspected, immediately terminate infusion and apply ice to the affected area. For IV administration only; do not administer by IM or SUBQ routes. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Secondary acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin. AML and MDS typically occur within 1 to 3 years of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: May cause tumor lysis syndrome and hyperuricemia (in patients with rapidly growing tumors). Urinary alkalinization and prophylaxis with an antihyperuricemic agent may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Doxorubicin clearance is decreased in patients with elevated serum bilirubin and toxicities may be increased.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children are at increased risk for developing delayed cardiotoxicity; long-term periodic cardiac function monitoring is recommended. A panel from the American Society of Pediatric Hematology/Oncology (ASPHO) and International Society of Pediatric Oncology (SIOP) recommends in favor of an anthracycline infusion duration of at least 1 hour in pediatric patients to reduce the potential for cardiotoxicity (ASPHO/SIOP [Loeffen 2017]). However, extravasation risks should also be minimized and the protocol infusion duration specified in a protocol should be followed, particularly if the patient is receiving dexrazoxane as a cardioprotectant. Doxorubicin may contribute to prepubertal growth failure in children; may also contribute to gonadal impairment (usually temporary). Radiation recall pneumonitis has been reported in children receiving concomitant dactinomycin and doxorubicin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation recipients: Use with caution in patients who have received radiation therapy; radiation recall may occur. May increase radiation-induced toxicity to the myocardium, mucosa, skin, and liver.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Formulations (conventional vs liposomal): Use caution when selecting product for preparation and dispensing; indications, dosages and adverse event profiles differ between conventional doxorubicin hydrochloride solution and doxorubicin liposomal. Both formulations are the same concentration. As a result, serious errors have occurred.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878433"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients are at increased risk for developing delayed cardiac toxicity and CHF during early adulthood due to an increasing census of long-term survivors; risk factors include: Young treatment age (&lt;5 years), cumulative exposure, and concomitant cardiotoxic therapy. Up to 40% of pediatric patients may have subclinical cardiac dysfunction and 5% to 10% may develop heart failure. Long-term monitoring is recommended for all pediatric patients (Long-Term Follow-Up Guidelines [COG 2018]).</p></div>
<div class="block foc drugH1Div" id="F163127"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (5 mL, 10 mL, 25 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adriamycin: 2 mg/mL (5 mL [DSC], 10 mL [DSC], 25 mL [DSC], 100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (5 mL, 10 mL, 25 mL, 75 mL [DSC], 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (1 ea); 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adriamycin: 10 mg (1 ea [DSC]); 50 mg (1 ea) [contains lactose monohydrate]</p></div>
<div class="block geq drugH1Div" id="F163112"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323122"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (DOXOrubicin HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $0.36 - $1.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Adriamycin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $315.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (DOXOrubicin HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $63.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $315.64</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866669"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (5 mL, 10 mL, 25 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (1 ea); 50 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F163130"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Doxorubicin is associated with a moderate to high emetic potential (depending on dose or regimen); antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>IV:</b> Administer IV push over at least 3 to 10 minutes or by continuous infusion (infusion via central venous line recommended). Do not administer IM or SubQ. Rate of administration varies by protocol, refer to individual protocol for details. Protect from light until completion of infusion. Avoid contact with alkaline solutions. Monitor for local erythematous streaking along vein and/or facial flushing (may indicate rapid infusion rate); decrease the rate if occurs.</p>
<p style="text-indent:0em;margin-top:2em;">Ensure appropriate product is being administered (conventional doxorubicin and doxorubicin [liposomal] are different products and are <b>NOT</b> interchangeable).</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane or dimethyl sulfate [DMSO]). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (ESMO/EONS [Perez Fidalgo 2012]); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dexrazoxane:</i> 1000 mg/m<sup>2</sup> (maximum dose: 2000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m<sup>2</sup> (maximum dose: 1000 mg) IV over 1 to 2 hours day 3; begin within 6 hours of extravasation. Day 2 and day 3 doses should be administered at approximately the same time (± 3 hours) as the dose on day 1 (Mouridsen 2007; ESMO/EONS [Perez Fidalgo 2012]). <b>Note:</b> Reduce dexrazoxane dose by 50% in patients with moderate to severe renal impairment (CrCl &lt;40 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DMSO:</i> Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (ESMO/EONS [Perez Fidalgo 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">Transcatheter arterial chemoembolization (TACE): For conventional TACE, doxorubicin was administered with lipiodol followed by particle embolization with an embolic agent (Lammer 2010). IV antibiotics were administered prior to the procedure and embolic material was injected through the catheter until hemostasis was achieved (Morse 2012). For drug-eluting bead TACE, patients received a 4 mL bead loaded with doxorubicin mixed with non-ionic contrast media (Lammer 2010). Refer to protocol and institutional policies for additional administration details.</p></div>
<div class="block admp drugH1Div" id="F52612632"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Doxorubicin is associated with a moderate or high emetic potential (depending on dose or regimen); antiemetics are recommended to prevent nausea and vomiting (POGO [Paw Cho Sing 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer IV push over at least 3 to 10 minutes or by continuous IV infusion (infusion via central venous line recommended). Do not administer IM or SubQ. Rate of administration varies by protocol; however, some experts recommend infusing anthracyclines over at least 1 hour to reduce the potential for cardiotoxicity (ASPHO/SIOP [Loeffen 2017]). Refer to individual protocol for details, particularly if the patient is receiving dexrazoxane as a cardioprotectant (including timing with respect to dexrazoxane administration); take precautions to minimize extravasation risks.</p>
<p style="text-indent:-2em;margin-left:2em;">Protect from light until completion of infusion. Avoid contact with alkaline solutions. Monitor for local erythematous streaking along vein and/or facial flushing (may indicate rapid infusion rate); decrease rate if occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Ensure appropriate product is being administered (conventional doxorubicin and doxorubicin [liposomal] are different products and are <b>NOT</b> interchangeable).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane (adults) or dimethyl sulfate [DMSO]) (see Management of Drug Extravasations for more details). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (Pérez Fidalgo 2012); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p></div>
<div class="block hazard drugH1Div" id="F49130976"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F163128"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, adjuvant therapy:</b> Treatment component of adjuvant therapy (multi-agent) in women with evidence of axillary lymph node involvement following resection of primary breast cancer</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Other cancers:</b> Treatment of acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer (transitional cell, metastatic), bone sarcoma (metastatic), breast cancer (metastatic), bronchogenic carcinoma (metastatic), Hodgkin lymphoma, non-Hodgkin lymphomas, neuroblastoma (metastatic), ovarian cancer (metastatic), soft tissue sarcoma (metastatic), thyroid carcinoma (metastatic), Wilms tumor (metastatic).</p></div>
<div class="block off-label drugH1Div" id="F25474960"><span class="drugH1">Use: Off-Label: Adult</span><p>Adrenocortical carcinoma, advanced; Adult T-cell leukemia/lymphoma; Endometrial carcinoma; Hepatocellular carcinoma (intermediate stage; chemoembolization); Hepatocellular carcinoma (metastatic); Multiple myeloma; Neuroendocrine tumors, pancreatic; Renal carcinoma (advanced); Salivary gland cancers (advanced); Thymomas and thymic malignancies; Uterine sarcoma; Waldenström macroglobulinemia</p></div>
<div class="block mst drugH1Div" id="F163208"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Conventional formulation (Adriamycin) may be confused with the liposomal formulation (Doxil)</p>
<p style="text-indent:-2em;margin-left:4em;">DOXOrubicin may be confused with DACTINomycin, DAUNOrubicin, DAUNOrubicin liposomal, doxapram, doxazosin, DOXOrubicin liposomal, epiRUBicin, IDArubicin, valrubicin</p>
<p style="text-indent:-2em;margin-left:4em;">Adriamycin may be confused with achromycin, Aredia, Idamycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Use caution when selecting product for preparation and dispensing; indications, dosages, rate of administration, and adverse event profiles differ between conventional DOXOrubicin hydrochloride solution and DOXOrubicin liposomal. Both formulations are the same concentration. As a result, serious errors have occurred.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">ADR is an error-prone abbreviation</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Rubex, a discontinued brand name for DOXOrubicin in the US, is a brand name for ascorbic acid in Ireland</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F163194"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (major), CYP3A4 (major), P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F163121"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ado-Trastuzumab Emtansine: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine.  Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bevacizumab: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of DOXOrubicin (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of DOXOrubicin (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of DOXOrubicin (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of DOXOrubicin (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of DOXOrubicin (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DOXOrubicin (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexrazoxane: May diminish the therapeutic effect of DOXOrubicin (Conventional). Management: Do not administer dexrazoxane for cardioprotection at the time of doxorubicin initiation. This recommendation does not apply to the use of dexrazoxane for other indications (eg, extravasation), or to the use of dexrazoxane later in treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fam-Trastuzumab Deruxtecan: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with fam-trastuzumab deruxtecan should avoid anthracycline-based therapy for up to 7 months after stopping fam-trastuzumab deruxtecan. Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Margetuximab: Anthracyclines may enhance the adverse/toxic effect of Margetuximab. Specifically, the risk of cardiac dysfunction may be increased.  Management: Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab due to an increased risk of cardiac dysfunction. If anthracyclines must be used with margetuximab monitor cardiac function closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mercaptopurine: DOXOrubicin (Conventional) may enhance the hepatotoxic effect of Mercaptopurine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): May increase the serum concentration of DOXOrubicin (Conventional). Management: Administer doxorubicin prior to paclitaxel if these agents are used in combination. Monitor cardiac function if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): May increase the serum concentration of DOXOrubicin (Conventional). Management: Administer doxorubicin prior to paclitaxel if these agents are used in combination. Monitor cardiac function if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of DOXOrubicin (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of DOXOrubicin (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of DOXOrubicin (Conventional). DOXOrubicin (Conventional) may decrease the serum concentration of Phenytoin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stavudine: DOXOrubicin (Conventional) may diminish the therapeutic effect of Stavudine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taxane Derivatives: May enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. Management: Consider separating doxorubicin and paclitaxel administration by as much time as possible, using liposomal doxorubicin or epirubicin instead of doxorubicin, or using docetaxel instead of paclitaxel. Monitor closely for cardiovascular and other toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trastuzumab: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab.  Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: DOXOrubicin (Conventional) may enhance the adverse/toxic effect of Vinflunine. Specifically, the risk for hematologic toxicities may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: DOXOrubicin (Conventional) may enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Conventional) may diminish the therapeutic effect of Zidovudine.  Management: Avoid concomitant use of doxorubicin and zidovudine due to the possibility of reduced zidovudine efficacy and increased myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49298501"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use highly effective contraception during treatment and for 6 months after the last doxorubicin dose.</p>
<p style="text-indent:0em;margin-top:2em;">Patients with partners who could become pregnant should use effective contraception during treatment and for 3 to 6 months (depending on manufacturer) after the last doxorubicin dose. In addition, patients with pregnant partners should use condoms during treatment and for at least 10 days after the last dose of doxorubicin.</p>
<p style="text-indent:0em;margin-top:2em;">Doxorubicin may impair fertility in males and females. In males, doxorubicin may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities; may also result in oligospermia, azoospermia, and permanent loss of fertility (sperm counts have been reported to return to normal levels in some men, occurring several years after the end of therapy). In females of reproductive potential, doxorubicin may cause infertility and result in amenorrhea; premature menopause can occur.</p></div>
<div class="block pri drugH1Div" id="F163135"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Doxorubicin crosses the placenta (Ryu 2014). First trimester exposure should be avoided (Azim 2010a; Azim 2010b). A neonatal echocardiogram and ECG are recommended following intrauterine anthracycline exposure (Amant 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Some pharmacokinetic properties of doxorubicin may be altered in pregnant patients (Ryu 2014; van Hasselt 2014). Use of doxorubicin in pregnant patients has been described for indications such as acute myeloid leukemia, breast cancer, and aggressive Hodgkin and non-Hodgkin lymphomas (Ali 2015; Azim 2011; Lishner 2016; Ring 2005).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology (ESMO) has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). If chemotherapy is indicated, it should <b>not</b> be administered in the first trimester, but may begin in the second trimester. There should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F5526739"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Doxorubicin and its metabolites are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the presence of doxorubicin in breast milk is available from a lactating woman treated for ovarian cancer. Doxorubicin was infused over 15 minutes at 7 months postpartum. Breast milk doxorubicin concentrations peaked 24 hours after treatment and were detectable for up to 72 hours after the dose. Peak doxorubicin concentrations in breast milk were 4.4 times greater than maternal plasma concentrations (Egan 1985). A second case evaluated doxorubicin in the breast milk following maternal treatment for stage IV diffuse large B-cell lymphoma at 4 months postpartum. Doxorubicin and the doxorubicinol metabolite were detectable in breast milk for 21 days after the first dose (Codacci-Pisanelli 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during doxorubicin therapy and for 10 days after the last doxorubicin dose. Others suggest breastfeeding should be avoided for at least 6 weeks after the last dose of doxorubicin (Codacci-Pisanelli 2019).</p></div>
<div class="block mop drugH1Div" id="F163125"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor cumulative (lifetime) anthracycline/doxorubicin dose. Monitor CBC with differential and platelet count (at baseline and regularly during treatment); LFTs (bilirubin, ALT/AST, alkaline phosphatase; at baseline and during treatment); renal function (creatinine), serum uric acid, and electrolytes (calcium, potassium, phosphate). Assess cardiac function (baseline, periodic, and follow-up): ECG, left ventricular ejection fraction (baseline and regularly during treatment; assess via echocardiography or multigated radionuclide angiography; use the same assessment method at all time points; increase the frequency of assessments as the cumulative dose exceeds 300 mg/m<sup>2</sup>). Evaluate pregnancy status prior to use in patients who could become pregnant. Monitor hydration status and for signs/symptoms of tumor lysis syndrome and secondary malignancies. Monitor infusion site.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional cardiovascular monitoring (ASCO [Armenian 2017], </i>
<i>ESC [Lyon 2022]):</i> Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking. Echocardiogram (transthoracic preferred, perform at baseline and 12 months after therapy completion for all patients; in addition, perform every 2 cycles and within 3 months after therapy completion for high- or very high-risk patients). Cardiac biomarkers (troponin and natriuretic peptide at baseline for high and very high-risk patients [may consider for low- and moderate-risk]; also prior to each cycle during anthracycline treatment and at 3 and 12 months after therapy completion for high- and very high-risk patients). In patients who develop signs/symptoms of cardiac dysfunction during therapy, echocardiogram is recommended for diagnostic workup; if echocardiogram is not available or feasible, a cardiac MRI (preferred) or MUGA scan may be utilized; obtain serum cardiac biomarkers. Refer to a cardiologist when clinically indicated.</p></div>
<div class="block pha drugH1Div" id="F163115"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Doxorubicin inhibits DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.</p></div>
<div class="block phk drugH1Div" id="F163132"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 809 to 1,214 L/m<sup>2</sup>; does not cross the blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: ~75%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily hepatic to doxorubicinol (active), then to inactive aglycones, conjugated sulfates, and glucuronides </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Distribution: ~5 minutes</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Terminal: 20 to 48 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Male: 54 hours; Female: 35 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (~40% as unchanged drug); urine (5% to 12% as unchanged drug and metabolites)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance:</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Infants and Children &lt;2 years: 813 mL/minute/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Children and Adolescents &gt;2 years: 1,540 mL/minute/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Adults: 324 to 809 mL/minutes/m<sup>2</sup> (appears to be higher in men than women)</p></div>
<div class="block phksp drugH1Div" id="F51153987"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance is reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">Obesity: Systemic clearance is significantly reduced in females with ideal body weight &gt;130%. There was a significant reduction in clearance without any change in V<sub>d</sub> in these patients when compared with healthy patients with &lt;115% ideal body weight.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F163136"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Colhidrol | Dalmonar | Doxocris | Doxokebir | Doxorubicin liposomal mrp | Doxorubicina delta farma | Doxorubicina fada | Doxorubicina filaxis | Doxorubicina gador | Doxorubicina glenmark | Doxorubicina Gobbi | Doxorubicina kemex | Doxorubicina servycal | Doxplax | Flavicina | Onkostatil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adriblastin | Doxo cell | Doxorubicin accord | Doxorubicin ebewe</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Accord doxorubicin | Adriamycin | Doxorubicin comp | Doxorubicin fot | Doxorubicin myx | Doxorubicin sz | L-doxorubicin | Lipodox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina | Doxorubicin accord | Doxorubicin actavis | Doxorubicine Teva | Doxorubin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Adriblastine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin | Doxorubicin ebewe</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de doxorrubicina | Docks | Doxolem | Doxopeg | Fauldoxo | Neoxane | Rubex | Rubidox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Adriblastin | Adriblastin rd | Doxorubicin bigmar | Doxorubicin ebewe | Doxorubicin sandoz | Doxorubicin teva | Doxorubicine | Doxorubicine bristol</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Adriblastine | Doxutec | Rubidox</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Doxopeg</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina | Doxolem | Doxopeg | Doxorrubicina | Doxorubicin | Doxorubicina | Doxorubicina clorhidrato | Doxorubin | Grana | Lipodox | Senfrenda | Zytokil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin | Doxorubicin Medac | Doxorubicin pharmagen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adriacept | Adriblastin | Adriblastina | Adricept | Adrimedac | Axidoxo | Celdoxome pegylated liposomal | Doxo cell | Doxorubichydrochloride teva | Doxorubicin | Doxorubicin accord | Doxorubicin actavis | Doxorubicin Bendalis | Doxorubicin hcl ods | Doxorubicin hcl omnicare | Doxorubicin Hcl Oncotrade | Doxorubicin hcl vitane | Doxorubicin hexal | Doxorubicin nc | Doxorubicinhydrochlorid bendalis | Doxorubicinhydrochlorid teva | Onkodox | Ribodoxo | Ribodoxo-l | Urokit doxo cell</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Adrim | Doxopeg</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin accord | Doxorubicin actavis | Doxorubicinum</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Adricin | Doxorubicin | Oncodox</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicina accord | Doxorubicina actavis | Doxorubicina Ferrer Farma | Doxorubicina tedec | Farmiblastina</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Doxutec | Zodox</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Doxorubicin accord | Doxorubicin actavis | Doxorubicin Medac | Doxorubicin pharmachemie</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adriblastine | Doxorubicine | Doxorubicine accord | Doxorubicine actavis | Doxorubicine arrow | Doxorubicine dakota | Doxorubicine Ebewe | Doxorubicine g gam | Doxorubicine Teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin | Doxorubicin sandoz | Doxorubin | Trav doxorubicin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin HCL | Doxorubin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Doxorubicin | Doxorubicin ebewe | Doxorubicin teva</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina pfs | Doxorubicin ebewe | Doxorubicin Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina rtu | Doxorubicin accord | Doxorubicin ebewe | Doxorubicin teva | Pallagicin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin | Doxorubicin pfizer | Kemodoxin | Rubidox | Sandobicin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin teva</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Adrib | Adrim | Cadria | Dobixin | Doxobin | Doxorubicin | Doxulip | Doxutec | Duxocin | Kemodoxa | Lipisol | Lipodox | Metodox | Nudoxa | Oncodox peg | Oncodria | Piglit | Zuvidox</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicina | Doxorubicina accord | Doxorubicina aurobindo | Doxorubicina ebewe | Doxorubicina hikma | Doxorubicina teva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">A.d.mycin | Adriblastina | Doxorubicin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Doxil | Doxorubicin hydrochloride Sandoz</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adrib | Adriblastina rtu | Adrim | Doxorubin | Doxutec | Rubidox | Zodox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A. d. mycin | A.D.M | A.d.mycin | Ad mycin | Adm | Adriamycin pfs | Adriamycin rdf | Adrubicin | Dobicin | Doxocin | Doxorubicin | Doxorubin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Doxotil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Doxolem ru | Doxorubicin | Doxorubicin accord | Doxorubicin teva | Rastocin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina pfs | Doxorubicin | Doxorubicin accord</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">D rubicin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Citoncubin | Doxopeg | Doxorubicina | Doxotec | Flexideminel | Metodox | Zodox | Zytokil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">A.D. Mycin | Adriamycin | Adriblastina | Adrim | DBL Doxorubicin | Doxlox | Doxorubicin | Doxorubicin DBL | Doxorubin | Lipodox</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Doxokal | Doxorubicin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina r.t.u. | Doxorubicine accord | Doxorubicine hcl actavis | Doxorubicine HCl CF | Doxorubicine HCl Ebewe | Doxorubicine HCl EuroCept | Doxorubicine HCl Sandoz | Doxorubicine Sandoz Hcl | Doxorubin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Celdoxome pegylated liposomal | Doxorubicin | Doxorubicin accord | Doxorubicin ebewe | Doxorubicin Meda</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Arrow Doxorubicin | Doxorubicin | Doxorubicin HCL</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dicladox | Doxocris | Doxopeg | Doxorubicina | Doxtie</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">A.D. Mycin | Adrim | Caspria | Doxoruba | Doxovid | Lipo Dox | Lypodoxo | Rubidox | Ruxodox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Doxocin | Doxorubicin | Doxorubicin ebewe | Doxorubin | Nagun 10 | Nagun 50 | Rubidox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adriblastin pfs | Doxorubicin ebewe | Doxorubicin Medac | Doxorubicin teva | Doxorubicine | Doxorubicinum Accord | Lipodox</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Adriamycin pfs | Adriamycin rdf | Doxorubicin | Doxorubicin HCL | Lipodox | Lipodox 50</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina | Doxo cell | Doxorrubicina | Doxorrubicina accord | Doxorrubicina Actavis | Fauldoxo</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Abinol | Clorhidrato de doxorrubicina liposomal | Colhidrol | Doxokebir | Doxorubicina 50 mg varifarma | Doxorubicina cipla | Doxorubicina fada | Doxorubicina fusa | Doxorubicina kirei | Doxorubicina libra | Doxorubicina sandoz | Doxorubicina tuteur | Doxplax | Flavicina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dharuxo | Doxorubicin ebewe | Doxorubicina accord | Doxorubicina actavis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Doxolek | Doxorubicin | Doxorubicin ebewe | Doxorubicin Ferein | Doxorubicin lans | Doxorubicin ronc</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Adrim | Doxorubicin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Doxorubicin accord | Doxorubicin actavis | Doxorubicin ebewe | Doxorubicin lederle | Doxorubicin Meda | Doxorubicin Stada | Doxorubicin teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Adriamycin | Adriamycin CS</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Doksorubicin accord | Doksorubicin Teva | Doxorubin | Lipodox</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina pfs | Doxorubicin | Doxorubicin actavis | Doxorubicin ebewe | Doxorubicin Medac</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina | Adrim | Doxorubicin | Doxorubicin DBL | Doxorubicin ebewe | Doxorubicin sandoz | Doxorubin | Lipo-Dox | Zodox</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina rd | Adriblastine | Cytodox | Doxorubicin ebewe</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin hexal | Doxorubicin kocak | Doxtu</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Doxlox | Doxor lyo | Doxorubicin | Lipo-Dox</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adrosal | Dopolo | Doxolek | Doxorubicin | Lipodox | Oncodox</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Robol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Antraciclin | Doxorrubicina | Doxorrumal | Doxorubicina glenmark | Doxplax</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adriblastina | Cipla Doxorubicin | Doxolip | Doxopeg | Doxorubicin | Doxorubicin accord | Doxorubicin hexal | Doxorubicin pch | Lipodox</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Doxorubicin hexal | Doxorubicina</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Adrim | Robol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adriamycin.1">
<a name="Adriamycin.1"></a>Adriamycin (doxorubicin) injection, USP [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26081614">
<a name="26081614"></a>Ali S, Jones GL, Culligan DJ, et al; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. <i>Br J Haematol</i>. 2015;170(4):487-495. doi:10.1111/bjh.13554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/26081614/pubmed" id="26081614" target="_blank">26081614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31435648">
<a name="31435648"></a>Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. <i>Ann Oncol</i>. 2019;30(10):1601-1612. doi: 10.1093/annonc/mdz228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/31435648/pubmed" id="31435648" target="_blank">31435648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27185849">
<a name="27185849"></a>Appel BE, Chen L, Buxton AB, et al. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. <i>J Clin Oncol</i>. 2016;34(20):2372-2379. doi: 10.1200/JCO.2015.65.3469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/27185849/pubmed" id="27185849" target="_blank">27185849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9849484">
<a name="9849484"></a>Arndt CA, Nascimento AG, Schroeder G, et al. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide. <i>Eur J Cancer</i>. 1998; 34(8):1224-1229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/9849484/pubmed" id="9849484" target="_blank">9849484</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007:99.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12767083">
<a name="12767083"></a>Assikis V, Buzdar A, Yang Y, et al. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. <i>Cancer</i>. 2003;97(11):2716-2723.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12767083/pubmed" id="12767083" target="_blank">12767083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21111624">
<a name="21111624"></a>Azim HA Jr, Del Mastro L, Scarfone G, et al. Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more. <i>Breast</i>. 2011;20(1):1-6. doi:10.1016/j.breast.2010.10.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/21111624/pubmed" id="21111624" target="_blank">21111624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20015593">
<a name="20015593"></a>Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. <i>Cancer Treat Rev</i>. 2010a;36(2):101-109. doi:10.1016/j.ctrv.2009.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20015593/pubmed" id="20015593" target="_blank">20015593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20018452">
<a name="20018452"></a>Azim HA Jr, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. <i>Cancer Treat Rev</i>. 2010b;36(2):110-121. doi:10.1016/j.ctrv.2009.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20018452/pubmed" id="20018452" target="_blank">20018452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12853357">
<a name="12853357"></a>Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. <i>Ann Oncol</i>. 2003; 14(7):1126-1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12853357/pubmed" id="12853357" target="_blank">12853357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11118462">
<a name="11118462"></a>Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico Rizzoli according to the istituto ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. <i>J Clin Oncol</i>. 2000;18(24):4016-4027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11118462/pubmed" id="11118462" target="_blank">11118462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14665607">
<a name="14665607"></a>Bamias A, Aravantinos G, Deliveliotis C, et al; Hellenic Cooperative Oncology Group. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group [published correction appears in <i>J Clin Oncol</i>. 2004;22(9):1771]. <i>J Clin Oncol</i>. 2004;22(2):220-228. doi: 10.1200/JCO.2004.02.152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/14665607/pubmed" id="14665607" target="_blank">14665607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21339382">
<a name="21339382"></a>Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. <i>Ann Oncol</i>. 2011;22(8):1859-1864. doi: 10.1093/annonc/mdq677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/21339382/pubmed" id="21339382" target="_blank">21339382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16172198">
<a name="16172198"></a>Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. <i>Endocr Relat</i>
<i>Cancer.</i> 2005;12:657-666. doi:10.1677/erc.1.01025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16172198/pubmed" id="16172198" target="_blank">16172198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26033801">
<a name="26033801"></a>Bielack SS, Smeland S, Whelan JS, et al; EURAMOS-1 investigators. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial. <i>J Clin Oncol</i>. 2015;33(20):2279-2287. doi: 10.1200/JCO.2014.60.0734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/26033801/pubmed" id="26033801" target="_blank">26033801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin</i>
<i>Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16176971">
<a name="16176971"></a>Bird BR, Elfiki T, Tucker O, O'Reilly S. Unilateral nail changes secondary to adriamycin: the protective effect of brachial plexopathy. <i>Ann Oncol</i>. 2006;17(3):527. doi:10.1093/annonc/mdj015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16176971/pubmed" id="16176971" target="_blank">16176971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15199092">
<a name="15199092"></a>Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. <i>J Clin Oncol</i>. 2004;22(14):2835-2841.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15199092/pubmed" id="15199092" target="_blank">15199092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1403038">
<a name="1403038"></a>Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. <i>J Clin Oncol</i>. 1992;10(10):1579-1591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/1403038/pubmed" id="1403038" target="_blank">1403038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-348293">
<a name="348293"></a>Bull JM, Tormey DC, Li SH, et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. <i>Cancer</i>. 1978;41(5):1649-1657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/348293/pubmed" id="348293" target="_blank">348293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21045191">
<a name="21045191"></a>Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. <i>Oncologist</i>. 2010;15(11):1227-1237. doi:10.1634/theoncologist.2009-0090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/21045191/pubmed" id="21045191" target="_blank">21045191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18818699">
<a name="18818699"></a>Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). <i>Leukemia</i>. 2009;23(1):153-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/18818699/pubmed" id="18818699" target="_blank">18818699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138821">
<a name="17138821"></a>Cairo MS, Gerrard M, Sposto R, et al FAB LMB96 International Study Committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <i>Blood</i>. 2007;109(7):2736-2743. doi: 10.1182/blood-2006-07-036665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/17138821/pubmed" id="17138821" target="_blank">17138821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33091356">
<a name="33091356"></a>Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematol.</i> 2020;7(11):e827-e837. doi:10.1016/S2352-3026(20)30224-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/33091356/pubmed" id="33091356" target="_blank">33091356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28456635">
<a name="28456635"></a>Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline [published correction appears in <i>J Urol</i>. 2017;198(5):1175]. <i>J Urol</i>. 2017;198(3):552-559. doi: 10.1016/j.juro.2017.04.086.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/28456635/pubmed" id="28456635" target="_blank">28456635</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 5.0. Published October 2018. Available at: http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33552401">
<a name="33552401"></a>Chong EG, Lee EH, Sail R, Denham L, Nagaraj G, Hsueh CT. Anthracycline-induced cardiotoxicity: a case report and review of literature. <i>World J Cardiol</i>. 2021;13(1):28-37. doi:10.4330/wjc.v13.i1.28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/33552401/pubmed" id="33552401" target="_blank">33552401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24821883">
<a name="24821883"></a>Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. <i>J Clin Oncol.</i> 2014;32(18):1889-1894. doi: 10.1200/JCO.2013.52.4785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/24821883/pubmed" id="24821883" target="_blank">24821883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668651">
<a name="12668651"></a>Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 [published correction appears in <i>J Clin Oncol</i>. 2003;21(11):2226].<i> J Clin Oncol</i>. 2003;21(8):1431-1439. doi: 10.1200/JCO.2003.09.081.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12668651/pubmed" id="12668651" target="_blank">12668651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31437753">
<a name="31437753"></a>Codacci-Pisanelli G, Honeywell RJ, Asselin N, et al. Breastfeeding during R-CHOP chemotherapy: please abstain! <i>Eur J Cancer</i>. 2019;119:107-111. doi:0.1016/j.ejca.2019.07.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/31437753/pubmed" id="31437753" target="_blank">31437753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3791831">
<a name="3791831"></a>Cohen CJ. Cytotoxic chemotherapy for patients with endometrial carcinoma. <i>Clin Obstet Cynaecol.</i> 1986;13(4):811-824.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/3791831/pubmed" id="3791831" target="_blank">3791831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20548096">
<a name="20548096"></a>Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. <i>Blood</i>. 2010; 116(12):2040-2045.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20548096/pubmed" id="20548096" target="_blank">20548096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29224502">
<a name="29224502"></a>Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. <i>N Engl J Med</i>. 2018;378(4):331-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/29224502/pubmed" id="29224502" target="_blank">29224502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12065556">
<a name="12065556"></a>Czauderna P, Mackinlay G, Perilongo G, et al; Liver Tumors Study Group of the International Society of Pediatric Oncology. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. <i>J Clin Oncol</i>. 2002;20(12):2798-2804. doi: 10.1200/JCO.2002.06.102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12065556/pubmed" id="12065556" target="_blank">12065556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18323546">
<a name="18323546"></a>Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. <i>J Clin Oncol</i>. 2008;26(8):1216-1222. doi:10.1200/JCO.2007.12.0733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/18323546/pubmed" id="18323546" target="_blank">18323546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25079173">
<a name="25079173"></a>DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. <i>Leukemia.</i> 2015;29(3):526-534. doi:10.1038/leu.2014.229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/25079173/pubmed" id="25079173" target="_blank">25079173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21563549">
<a name="21563549"></a>Debaere D, Vander Poorten V, Nuyts S, et al. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. <i>B-ENT</i>. 2011;7(1):1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/21563549/pubmed" id="21563549" target="_blank">21563549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22718839">
<a name="22718839"></a>Delarue R, Haioun C, Ribrag V, et al; Groupe d'Etude des Lymphomes de l'Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Blood</i>. 2013;121(1):48-53. doi: 10.1182/blood-2011-09-370320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/22718839/pubmed" id="22718839" target="_blank">22718839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12802024">
<a name="12802024"></a>Diehl V, Franklin J, Pfreundschuh M, et al; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. <i>N Engl J Med</i>. 2003;348(24):2386-2395. doi:10.1056/NEJMoa022473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12802024/pubmed" id="12802024" target="_blank">12802024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976420">
<a name="26976420"></a>Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016;34(13):1544-1557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/26976420/pubmed" id="26976420" target="_blank">26976420</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Doxorubicin [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; March 2017.</div>
</li>
<li>
<div class="reference">
                  Doxorubicin [prescribing information]. New York, NY: Pfizer Labs; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doxorubicin.3">
<a name="Doxorubicin.3"></a>Doxorubicin [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DoxorubicinHCl.1">
<a name="DoxorubicinHCl.1"></a>Doxorubicin Hydrochloride for Injection, USP, 2mg/mL vial [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23574119">
<a name="23574119"></a>Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. <i>N Engl J Med</i>. 2013;368(15):1408-1416. doi:10.1056/NEJMoa1214561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/23574119/pubmed" id="23574119" target="_blank">23574119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20717755">
<a name="20717755"></a>Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. <i>Med Oncol</i>. 2011;28(4):1530-1533. doi:10.1007/s12032-010-9649-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20717755/pubmed" id="20717755" target="_blank">20717755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4075315">
<a name="4075315"></a>Egan PC, Costanza ME, Dodion P, Egorin MJ, Bachur NR. Doxorubicin and cisplatin excretion into human milk. <i>Cancer Treat Rep</i>. 1985;69(12):1387-1389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/4075315/pubmed" id="4075315" target="_blank">4075315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8315424">
<a name="8315424"></a>Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. <i>J Clin Oncol</i>. 1993;11(7):1269-1275. doi:10.1200/JCO.1993.11.7.1269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/8315424/pubmed" id="8315424" target="_blank">8315424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28795993">
<a name="28795993"></a>Ehrlich P, Chi YY, Chintagumpala MM, et al. Results of the first prospective multi-institutional treatment study in children with bilateral Wilms tumor (AREN0534): a report from the Children's Oncology Group. <i>Ann Surg</i>. 2017;266(3):470-478. doi: 10.1097/SLA.0000000000002356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/28795993/pubmed" id="28795993" target="_blank">28795993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2504890">
<a name="2504890"></a>Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. <i>J Clin Oncol</i>. 1989;7(9):1208-1216. doi:10.1200/JCO.1989.7.9.1208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/2504890/pubmed" id="2504890" target="_blank">2504890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19704068">
<a name="19704068"></a>Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. <i>J Clin Oncol</i>. 2009;27(27):4548-4554. doi:10.1200/JCO.2008.19.8820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/19704068/pubmed" id="19704068" target="_blank">19704068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818855">
<a name="20818855"></a>Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. <i>N Engl J Med</i>. 2010;363(7):640-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20818855/pubmed" id="20818855" target="_blank">20818855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22551107">
<a name="22551107"></a>Fassnacht M, Terzolo M, Allolio B, et al; FIRM-ACT study group. Combination chemotherapy in advanced adrenocortical carcinoma. <i>N Engl J Med</i>. 2012;366(23):2189-2197. doi:10.1056/NEJMoa1200966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/22551107/pubmed" id="22551107" target="_blank">22551107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10424207">
<a name="10424207"></a>Felker GM, Hu W, Hare JM, Hruban RH, Baughman KL, Kasper EK. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. <i>Medicine (Baltimore)</i>. 1999;78(4):270-283. doi:10.1097/00005792-199907000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/10424207/pubmed" id="10424207" target="_blank">10424207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2202791">
<a name="2202791"></a>Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. <i>J Clin Oncol</i>. 1990;8(9):1483-1496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/2202791/pubmed" id="2202791" target="_blank">2202791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7251903">
<a name="7251903"></a>Fitter W, deSa DJ, Pai KR. Adriamycin cardiotoxicity: report of an unusual case with features resembling endomyocardial fibrosis. <i>J Clin Pathol</i>. 1981;34(6):602-605. doi:10.1136/jcp.34.6.602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/7251903/pubmed" id="7251903" target="_blank">7251903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al, “Hepatotoxicity of Chemotherapy,” <i>Semin Oncol</i>, 2006;33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, et al, “Cardiotoxicity of Cancer Therapy,” <i>J Clin Oncol</i>, 2005;23(30):7685-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2049749">
<a name="2049749"></a>Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. <i>Cancer</i>. 1991;68(1):30-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/2049749/pubmed" id="2049749" target="_blank">2049749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17233819">
<a name="17233819"></a>Garcia-Suarez J, Banas H, Arribas I, De Miguel D, Pascual T, Burgaleta C. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. <i>Br J Haematol</i>. 2007;136(2):276-285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/17233819/pubmed" id="17233819" target="_blank">17233819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18625886">
<a name="18625886"></a>Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood</i>. 2008;112(7):2687-2693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/18625886/pubmed" id="18625886" target="_blank">18625886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29082519">
<a name="29082519"></a>Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. <i>Br J Haematol</i>. 2017;179(5):739-747. doi: 10.1111/bjh.14951.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/29082519/pubmed" id="29082519" target="_blank">29082519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22940833">
<a name="22940833"></a>Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i>. 2013;27(5):1174-1177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/22940833/pubmed" id="22940833" target="_blank">22940833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25066629">
<a name="25066629"></a>Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. <i>Br J Haematol</i>. 2014;167(3):394-401. doi: 10.1111/bjh.13040.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/25066629/pubmed" id="25066629" target="_blank">25066629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12697883">
<a name="12697883"></a>Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. <i>J Clin Oncol</i>. 2003;21(8):1574-1580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12697883/pubmed" id="12697883" target="_blank">12697883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9850017">
<a name="9850017"></a>Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. <i>J Clin Oncol</i>. 1998;16(12):3744-3751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/9850017/pubmed" id="9850017" target="_blank">9850017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16547940">
<a name="16547940"></a>Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. <i>Pediatr Blood Cancer</i>. 2007;48(5):493-499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16547940/pubmed" id="16547940" target="_blank">16547940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594313">
<a name="12594313"></a>Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. <i>N Engl J Med</i>. 2003;348(8):694-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12594313/pubmed" id="12594313" target="_blank">12594313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12944571">
<a name="12944571"></a>Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published correction appears in <i>N Engl J Med</i>. 2003;349(19):1880]. <i>N Engl J Med</i>. 2003;349(9):859-866. doi: 10.1056/NEJMoa022148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12944571/pubmed" id="12944571" target="_blank">12944571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21298497">
<a name="21298497"></a>Haas NB, Lin X, Manola J, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. <i>Med Oncol</i>. 2012;29(2):761-767. doi:10.1007/s12032-011-9829-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/21298497/pubmed" id="21298497" target="_blank">21298497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35620259">
<a name="35620259"></a>Hakami T. Acute liver failure due to hepatitis B virus reactivation induced by doxorubicin and cyclophosphamide chemotherapy for adjuvant treatment of breast cancer: a case report. <i>Clin Case Rep</i>. 2022;10(5):e05894. doi:10.1002/ccr3.5894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/35620259/pubmed" id="35620259" target="_blank">35620259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32675783">
<a name="32675783"></a>Halfdanarson TR, Strosberg JR, Tang L, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. <i>Pancreas</i>. 2020;49(7):863-881. doi:10.1097/MPA.0000000000001597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/32675783/pubmed" id="32675783" target="_blank">32675783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37362481">
<a name="37362481"></a>Hassan MA, Batta Y, Afzal MA, Grewal N. Chemotherapy-induced atrial fibrillation with rapid ventricular response in a patient with pleomorphic rhabdomyosarcoma: a case report and approach to management. <i>Cureus</i>. 2023;15(5):e39375. doi:10.7759/cureus.39375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/37362481/pubmed" id="37362481" target="_blank">37362481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27313086">
<a name="27313086"></a>Hermine O, Hoster E, Walewski J, et al; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i>. 2016;388(10044):565-575. doi: 10.1016/S0140-6736(16)00739-X.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/27313086/pubmed" id="27313086" target="_blank">27313086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16123223">
<a name="16123223"></a>Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma study group. <i>Blood</i>. 2005;106(12):3725-3732. doi:10.1182/blood-2005-01-0016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16123223/pubmed" id="16123223" target="_blank">16123223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19108877">
<a name="19108877"></a>Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology group study. <i>Gynecol Oncol.</i> 2009;112(3):543-552. doi:10.1016/j.ygyno.2008.11.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/19108877/pubmed" id="19108877" target="_blank">19108877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11821442">
<a name="11821442"></a>Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. <i>J Clin Oncol</i>. 2002;20(3):630-637. doi:10.1200/JCO.2002.20.3.630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11821442/pubmed" id="11821442" target="_blank">11821442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522922">
<a name="30522922"></a>Horwitz S, O'Connor OA, Pro B, et al; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i>. 2019;393(10168):229-240. doi:10.1016/S0140-6736(18)32984-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/30522922/pubmed" id="30522922" target="_blank">30522922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3458999">
<a name="3458999"></a>Ishii E, Hara T, Ohkubo K, et al, “Treatment of Childhood Acute Lymphoblastic Leukemia With Intermediate Dose Cytosine Arabinoside and Adriamycin,” <i>Med Pediatr Oncol</i>, 1986, 14(2):73-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/3458999/pubmed" id="3458999" target="_blank">3458999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31852092">
<a name="31852092"></a>Jang LC, Choi YJ. Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer: a case report. <i>Medicine (Baltimore)</i>. 2019;98(50):e18249. doi:10.1097/MD.0000000000018249<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/31852092/pubmed" id="31852092" target="_blank">31852092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol.</i> 2010;21(7):1395-1403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27332902">
<a name="27332902"></a>Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. <i>N Engl J Med</i>. 2016;374(25):2419-2429. doi:10.1056/NEJMoa1510093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/27332902/pubmed" id="27332902" target="_blank">27332902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2525400">
<a name="2525400"></a>Jones AP, Crawford SM. Anthracycline-induced toxicity affecting palmar and plantar skin. <i>Br J Cancer</i>. 1989;59(5):814. doi:10.1038/bjc.1989.170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/2525400/pubmed" id="2525400" target="_blank">2525400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16572419">
<a name="16572419"></a>Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. <i>Pediatr Blood Cancer</i>. 2006;47(1):22-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16572419/pubmed" id="16572419" target="_blank">16572419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9607422">
<a name="9607422"></a>Kaneko M, Nishihira H, Mugishima H, et al. Stratification of treatment of stage 4 Neuroblastoma patients based on N-myc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan. <i>Med Pediatr Oncol.</i> 1998;31(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/9607422/pubmed" id="9607422" target="_blank">9607422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12439032">
<a name="12439032"></a>Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. <i>J Pediatr Hematol Oncol. </i>2002;24(8):613-621.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12439032/pubmed" id="12439032" target="_blank">12439032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15481055">
<a name="15481055"></a>Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Cancer</i>. 2004;101(12):2788-2801. doi:10.1002/cncr.20668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15481055/pubmed" id="15481055" target="_blank">15481055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29738613">
<a name="29738613"></a>Keller FG, Castellino SM, Chen L, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. <i>Cancer</i>. 2018;124(15):3210-3219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/29738613/pubmed" id="29738613" target="_blank">29738613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12078889">
<a name="12078889"></a>Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.<i> Ann Oncol</i>. 2002;13(Suppl 1):107-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12078889/pubmed" id="12078889" target="_blank">12078889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21079154">
<a name="21079154"></a>Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. <i>Blood</i>. 2011;117(9):2596-2603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/21079154/pubmed" id="21079154" target="_blank">21079154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15140551">
<a name="15140551"></a>Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. <i>Lung Cancer.</i> 2004;44(3):369-379. doi:10.1016/j.lungcan.2003.12.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15140551/pubmed" id="15140551" target="_blank">15140551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11306728">
<a name="11306728"></a>King PD and Perry MC, “Hepatotoxicity of Chemotherapy,” <i>Oncologist</i>, 2001, 6(2):162-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11306728/pubmed" id="11306728" target="_blank">11306728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15570077">
<a name="15570077"></a>Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. <i>J Clin Oncol</i>. 2004;22(23):4762-4771. doi:10.1200/JCO.2004.04.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15570077/pubmed" id="15570077" target="_blank">15570077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23890779">
<a name="23890779"></a>Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. <i>Lancet Oncol</i>. 2013;14(10):999-1008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/23890779/pubmed" id="23890779" target="_blank">23890779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol.</i> 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22719160">
<a name="22719160"></a>Kumar S, Marfatia R, Tannenbaum S, Yang C, Avelar E. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. <i>Tex Heart Inst J</i>. 2012;39(3):424-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/22719160/pubmed" id="22719160" target="_blank">22719160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7527454">
<a name="7527454"></a>Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. <i>J Clin Oncol</i>. 1994;12(12):2607-2613. doi: 10.1200/JCO.1994.12.12.2607.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/7527454/pubmed" id="7527454" target="_blank">7527454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8622067">
<a name="8622067"></a>Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. <i>J Clin Oncol</i>. 1996;14(5):1526-1531.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/8622067/pubmed" id="8622067" target="_blank">8622067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15160953">
<a name="15160953"></a>Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. <i>Leuk Lymphoma.</i> 2004;45(4):761-767. doi: 10.1080/1042819031000141301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15160953/pubmed" id="15160953" target="_blank">15160953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19908093">
<a name="19908093"></a>Lammer J, Malagari K, Vogl T, et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. <i>Cardiovasc Intervent Radiol</i>. 2010;33(1):41-52. doi: 10.1007/s00270-009-9711-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/19908093/pubmed" id="19908093" target="_blank">19908093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27114587">
<a name="27114587"></a>Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. <i>J Clin Oncol</i>. 2016;34(20):2380-2388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/27114587/pubmed" id="27114587" target="_blank">27114587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7718875">
<a name="7718875"></a>Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. <i>Blood</i>. 1995;85(8):2025-2037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/7718875/pubmed" id="7718875" target="_blank">7718875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16763282">
<a name="16763282"></a>Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. <i>J Clin Oncol</i>. 2006;24(17):2673-2678. doi:10.1200/JCO.2005.05.3025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16763282/pubmed" id="16763282" target="_blank">16763282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860952">
<a name="12860952"></a>Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. <i>J Clin Oncol</i>. 2003;21(14):2732-2739.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12860952/pubmed" id="12860952" target="_blank">12860952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15248028">
<a name="15248028"></a>Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. <i>Cancer Chemother Pharmacol</i>. 2004;54(5):385-390. doi: 10.1007/s00280-004-0837-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15248028/pubmed" id="15248028" target="_blank">15248028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879381">
<a name="8879381"></a>Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. <i>Ann Oncol</i>. 1996;7(6):640-642. doi:10.1093/oxfordjournals.annonc.a010684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/8879381/pubmed" id="8879381" target="_blank">8879381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol</i>. 2016;34(5):501-508. doi:10.1200/JCO.2015.62.4445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29077260">
<a name="29077260"></a>Loeffen EAH, van Dalen EC, Mulder RL, et al. The duration of anthracycline infusion should be at least one hour in children with cancer: A clinical practice guideline [published online October 27, 2017]. <i>Pediatr Blood Cancer</i>. 2018;65(2).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/29077260/pubmed" id="29077260" target="_blank">29077260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8201378">
<a name="8201378"></a>Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. <i>J Clin Oncol</i>. 1994;12(6):1164-1168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/8201378/pubmed" id="8201378" target="_blank">8201378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27569442">
<a name="27569442"></a>Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomized controlled trial. <i>Lancet Oncol.</i> 2016;17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/27569442/pubmed" id="27569442" target="_blank">27569442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15930421">
<a name="15930421"></a>Martin M, Pienkowski T, Mackey J, et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. <i>N Engl J Med</i>. 2005;352(22):2302-2313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15930421/pubmed" id="15930421" target="_blank">15930421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519894">
<a name="10519894"></a>Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-<i>cis</i>-retinoic acid. Children's Cancer Group. <i>N Engl J Med.</i> 1999;341(16):1165-1173. doi: 10.1056/NEJM199910143411601.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/10519894/pubmed" id="10519894" target="_blank">10519894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-791473">
<a name="791473"></a>McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. <i>Cancer</i>. 1976;38(4):1484-1493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/791473/pubmed" id="791473" target="_blank">791473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25925990">
<a name="25925990"></a>McMeekin S, Dizon D, Barter J, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. <i>Gynecol Oncol</i>. 2015;138(1):18-23. doi:10.1016/j.ygyno.2015.04.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/25925990/pubmed" id="25925990" target="_blank">25925990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12181251">
<a name="12181251"></a>Mead GM, Sydes MR, Walewski J, et al; UKLG LY06 collaborators. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. <i>Ann Oncol.</i> 2002;13(8):1264-1274. doi: 10.1093/annonc/mdf253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/12181251/pubmed" id="12181251" target="_blank">12181251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30932732">
<a name="30932732"></a>Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. <i>J Clin Oncol.</i> 2019;37(14):1228-1263. doi:10.1200/JCO.18.02096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/30932732/pubmed" id="30932732" target="_blank">30932732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1310159">
<a name="1310159"></a>Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. <i>N Engl J Med</i>. 1992;326(8):519-523. doi:10.1056/NEJM199202203260804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/1310159/pubmed" id="1310159" target="_blank">1310159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22280845">
<a name="22280845"></a>Morse MA, Hanks BA, Suhocki P, et al. Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. <i>Clin Colorectal Cancer</i>. 2012;11(3):185-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/22280845/pubmed" id="22280845" target="_blank">22280845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17185744">
<a name="17185744"></a>Mouridsen HT, Langer SW, Buter J, et al, “Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies,” <i>Ann Oncol</i>, 2007, 18(3):546-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/17185744/pubmed" id="17185744" target="_blank">17185744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19770626">
<a name="19770626"></a>Ogilvie CM, Crawford EA, Siotcavage RL, et al. Treatment of adult rhabdomyosarcoma. <i>Am J Clin Oncol</i>. 2010;33(2):128-131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/19770626/pubmed" id="19770626" target="_blank">19770626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6344983">
<a name="6344983"></a>Omura GA, Major FJ, Blessing JA, et al. A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. <i>Cancer</i>. 1983;52(4):626-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/6344983/pubmed" id="6344983" target="_blank">6344983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10894865">
<a name="10894865"></a>Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. <i>J Clin Oncol</i>. 2000;18(14):2665-2675.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/10894865/pubmed" id="10894865" target="_blank">10894865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25810263">
<a name="25810263"></a>Parikh NS, Howard SC, Chantada G, et al; International Society of Pediatric Oncology. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. <i>Pediatr Blood Cancer</i>. 2015;62(8):1305-1316. doi: 10.1002/pbc.25501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/25810263/pubmed" id="25810263" target="_blank">25810263</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Park J, Bagatell R. Neuroblastoma. In: Lanzkowsky P, Lipton J, Fish J, eds. <i>Lanzkowsky's Manual of Pediatric Hematology and Oncology</i>. 6th ed. London, UK: Academic Press; 2016:473-490.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16396674">
<a name="16396674"></a>Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. <i>BMC Cancer</i>. 2006;6:3. doi: 10.1186/1471-2407-6-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16396674/pubmed" id="16396674" target="_blank">16396674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18802150">
<a name="18802150"></a>Paulussen M, Craft AW, Lewis I, et al; European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. <i>J Clin Oncol</i>. 2008;26(27):4385-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/18802150/pubmed" id="18802150" target="_blank">18802150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi: 10.1002/pbc.27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(Suppl 6):vi160-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14982884">
<a name="14982884"></a>Pfreundschuh M, Trümper L, Kloess M, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. <i>Blood</i>. 2004;104(3):626-633. doi:10.1182/blood-2003-06-2094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/14982884/pubmed" id="14982884" target="_blank">14982884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18302711">
<a name="18302711"></a>Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. <i>Br J Haematol</i>. 2008;140(6):625-634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/18302711/pubmed" id="18302711" target="_blank">18302711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24821881">
<a name="24821881"></a>Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.<i> J Clin Oncol. </i>2014;32(18):1895-1901. doi: 10.1200/JCO.2013.53.2465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/24821881/pubmed" id="24821881" target="_blank">24821881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28273993">
<a name="28273993"></a>Prajapati VB, Madhyastha S, Acharya R, Gopalaswamy V, Doddamani A. Cyclophosphamide and doxorubicin induced melanonychia: a case report. <i>J Clin Diagn Res</i>. 2017;11(1):OD04-OD05. doi:10.7860/JCDR/2017/23041.9216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/28273993/pubmed" id="28273993" target="_blank">28273993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11078495">
<a name="11078495"></a>Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. <i>J Clin Oncol. </i>2000;18(22):3819-3828. doi: 10.1200/JCO.2000.18.22.3819.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11078495/pubmed" id="11078495" target="_blank">11078495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7799012">
<a name="7799012"></a>Pritchard J, Imeson J, Barnes J, et al. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study. <i>J Clin Oncol. </i>1995;13(1):124-133. doi: 10.1200/JCO.1995.13.1.124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/7799012/pubmed" id="7799012" target="_blank">7799012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16330675">
<a name="16330675"></a>Randall ME, Filiaci VL, Muss H, et al; Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. <i>J Clin Oncol</i>. 2006;24(1):36-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16330675/pubmed" id="16330675" target="_blank">16330675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19273394">
<a name="19273394"></a>Rehwaldt M, Wickham R, Purl S, et al. Self-care strategies to cope with taste changes after chemotherapy. <i>Oncol Nurs Forum</i>. 2009;36(2):E47-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/19273394/pubmed" id="19273394" target="_blank">19273394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15961766">
<a name="15961766"></a>Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. <i>J Clin Oncol</i>. 2005;23:4192-4197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15961766/pubmed" id="15961766" target="_blank">15961766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24428673">
<a name="24428673"></a>Rizzieri DA, Johnson JL, Byrd JC, et al; Alliance for Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002. <i>Br J Haematol</i>. 2014;165(1):102-111. doi:10.1111/bjh.12736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/24428673/pubmed" id="24428673" target="_blank">24428673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16236738">
<a name="16236738"></a>Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. <i>N Engl J Med</i>. 2005;353(16):1673-1684. doi:10.1056/NEJMoa052122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16236738/pubmed" id="16236738" target="_blank">16236738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9649151">
<a name="9649151"></a>Rubie H, Michon J, Plantaz D, et al. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). <i>Br J Cancer</i>. 1998;77(12):2310-2317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/9649151/pubmed" id="9649151" target="_blank">9649151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11464897">
<a name="11464897"></a>Rubie H, Plantaz D, Coze C, et al; Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique. <i>Med Pediatr Oncol</i>. 2001;36(1):247-250. doi: 10.1002/1096-911X(20010101)36:1&lt;247::AID-MPO1061&gt;3.0.CO;2-Z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11464897/pubmed" id="11464897" target="_blank">11464897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24531558">
<a name="24531558"></a>Ryu RJ, Eyal S, Kaplan HG, et al. Pharmacokinetics of doxorubicin in pregnant women. <i>Cancer Chemother Pharmacol</i>. 2014;73(4):789-797. doi: 10.1007/s00280-014-2406-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/24531558/pubmed" id="24531558" target="_blank">24531558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandhu.1">
<a name="Sandhu.1"></a>Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N; ADDIKD Guideline Working Group. International consensus guideline for anticancer drug dosing in kidney dysfunction 2022. https://www.eviq.org.au/clinical-resources/addikd-guideline/4174-anticancer-drug-dosing-in-kidney-dysfunction. Published 2022. Accessed November 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7602342">
<a name="7602342"></a>Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>J Clin Oncol</i>. 1995;13(7):1537-1545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/7602342/pubmed" id="7602342" target="_blank">7602342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32101663">
<a name="32101663"></a>Schmid P, Cortes J, Pusztai L, et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. <i>N Engl J Med</i>. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/32101663/pubmed" id="32101663" target="_blank">32101663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20660290">
<a name="20660290"></a>Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Blood</i>. 2010;116(18):3418-3425. doi:10.1182/blood-2010-02-270785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20660290/pubmed" id="20660290" target="_blank">20660290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19584400">
<a name="19584400"></a>Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/19584400/pubmed" id="19584400" target="_blank">19584400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11389005">
<a name="11389005"></a>Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. <i>Blood</i>. 2001;97(12):3699-3706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11389005/pubmed" id="11389005" target="_blank">11389005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7803884">
<a name="7803884"></a>Seifert CF, Nesser ME, and Thompson DF, “Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity,” <i>Ann Pharmacother</i>, 1994, 28(9):1063-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/7803884/pubmed" id="7803884" target="_blank">7803884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19414678">
<a name="19414678"></a>Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. <i>J Clin Oncol.</i> 2009;27(16):2592-2597. doi:10.1200/JCO.2008.19.0256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/19414678/pubmed" id="19414678" target="_blank">19414678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22802322">
<a name="22802322"></a>Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. <i>J Clin Oncol</i>. 2012;30(24):2946-2955.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/22802322/pubmed" id="22802322" target="_blank">22802322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3137469">
<a name="3137469"></a>Speyer JL, Green MD, Kramer E, et al, “Protective Effect of the Bispiperazinedione ICRF-187 Against Doxorubicin-Induced Cardiac Toxicity in Women With Advanced Breast Cancer,” <i>N Engl J Med</i>, 1988, 319(12):745-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/3137469/pubmed" id="3137469" target="_blank">3137469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11352955">
<a name="11352955"></a>Sternberg CN, de Mulder PH, Schornagel JH, et al; European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. <i>J Clin Oncol</i>. 2001;19(10):2638-2646. doi: 10.1200/JCO.2001.19.10.2638.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11352955/pubmed" id="11352955" target="_blank">11352955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16330205">
<a name="16330205"></a>Sternberg CN, de Mulder P, Schornagel JH, et al; EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. <i>Eur J Cancer</i>. 2006;42(1):50-54. doi: 10.1016/j.ejca.2005.08.032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16330205/pubmed" id="16330205" target="_blank">16330205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37180802">
<a name="37180802"></a>Suto H, Suto M, Inui Y, Okamura A. Late-onset doxorubicin-induced congestive heart failure in an elderly cancer survivor: a case report. <i>Front Cardiovasc Med</i>. 2023;10:1124276. doi:10.3389/fcvm.2023.1124276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/37180802/pubmed" id="37180802" target="_blank">37180802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8751554">
<a name="8751554"></a>Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. <i>Gynecol Oncol</i>. 1996;62(2):226-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/8751554/pubmed" id="8751554" target="_blank">8751554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28057664">
<a name="28057664"></a>Swain SM, Schneeweiss A, Gianni L, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. <i>Ann Oncol</i>. 2017;28(4):761-768. doi:10.1093/annonc/mdw695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/28057664/pubmed" id="28057664" target="_blank">28057664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22911615">
<a name="22911615"></a>Tebbi CK, Mendenhall NP, London WB, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2012;59(7):1259-1265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/22911615/pubmed" id="22911615" target="_blank">22911615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502413">
<a name="16502413"></a>Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i>. 2006;106(7):1569-8150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/16502413/pubmed" id="16502413" target="_blank">16502413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34904799">
<a name="34904799"></a>Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. <i>N Engl J Med</i>. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/34904799/pubmed" id="34904799" target="_blank">34904799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15794864">
<a name="15794864"></a>Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. <i>Clin Lymphoma</i>. 2005;5(4):273-277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/15794864/pubmed" id="15794864" target="_blank">15794864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968021">
<a name="17968021"></a>Tsukasaki K, Utsunomiya A, Fukuda H, et al; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. <i>J Clin Oncol</i>. 2007;25(34):5458-5464. doi:10.1200/JCO.2007.11.9958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/17968021/pubmed" id="17968021" target="_blank">17968021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin</i>
<i>Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713311">
<a name="24713311"></a>van Hasselt JGC, Van Calsteren K, Heyns L, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. <i>Ann Oncol</i>. 2014;25(10)2059-2065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/24713311/pubmed" id="24713311" target="_blank">24713311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11001674">
<a name="11001674"></a>von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. <i>J Clin Oncol.</i> 2000;18(17):3068-3077. doi: 10.1200/JCO.2000.18.17.3068.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11001674/pubmed" id="11001674" target="_blank">11001674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10080612">
<a name="10080612"></a>Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. <i>J Clin Oncol</i>. 1999;17(2):658-667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/10080612/pubmed" id="10080612" target="_blank">10080612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23358966">
<a name="23358966"></a>Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. <i>J Clin Oncol</i>. 2013;31(9):1202-1210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/23358966/pubmed" id="23358966" target="_blank">23358966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25421877">
<a name="25421877"></a>Whelan JS, Bielack SS, Marina N, et al; EURAMOS collaborators. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. <i>Ann Oncol</i>. 2015;26(2):407-414. doi: 10.1093/annonc/mdu526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/25421877/pubmed" id="25421877" target="_blank">25421877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23863059">
<a name="23863059"></a>Wilson WH, Grant C, Dunleavy K. Therapy in primary mediastinal B-cell lymphoma. <i>N Engl J Med</i>. 2013;369(3):283-284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/23863059/pubmed" id="23863059" target="_blank">23863059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11929754">
<a name="11929754"></a>Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. <i>Blood</i>. 2002;99(8):2685-2693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/11929754/pubmed" id="11929754" target="_blank">11929754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23863060">
<a name="23863060"></a>Woessmann W, Lisfeld J, Burkhardt B; NHL-BFM Study Group. Therapy in primary mediastinal B-cell lymphoma. <i>N Engl J Med</i>. 2013;369(3):282. doi: 10.1056/NEJMc1305983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/23863060/pubmed" id="23863060" target="_blank">23863060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21280197">
<a name="21280197"></a>Wrobel G, Mauguen A, Rosolen A, et al. Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. <i>Pediatr Blood Cancer</i>. 2011;56(7):1071-1077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/21280197/pubmed" id="21280197" target="_blank">21280197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8137454">
<a name="8137454"></a>Yoshida H, Goto M, Honda A, et al. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. <i>Cancer Chemother Pharmacol</i>. 1994;33(6):450-454. doi:10.1007/BF00686499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/8137454/pubmed" id="8137454" target="_blank">8137454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2067035">
<a name="2067035"></a>Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. <i>J Natl Cancer Inst</i>. 1991;83(13):926-932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/2067035/pubmed" id="2067035" target="_blank">2067035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27567406">
<a name="27567406"></a>Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2016;37(36):2768-2801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/27567406/pubmed" id="27567406" target="_blank">27567406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20406943">
<a name="20406943"></a>Zsíros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. <i>J Clin Oncol</i>. 2010;28(15):2584-2590. doi: 10.1200/JCO.2009.22.4857.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxorubicin-conventional-drug-information/abstract-text/20406943/pubmed" id="20406943" target="_blank">20406943</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9391 Version 474.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
